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Cancro da mama, angiogénese, VEGF-A, ANG-2, terapia anti-angiogénica, 
imunoterapia mediada por agonistas do recetor CD40 
A angiogénese é um processo crucial para o crescimento, progressão e 
disseminação do cancro da mama, tornando-se assim um alvo terapêutico 
promissor. A maioria dos estudos clínicos de terapias anti-angiogénicas em 
cancro da mama baseiam-se na neutralização do fator de crescimento 
endotelial vascular (VEGF), uma vez que este apresenta um papel dominante 
na angiogénese tumoral. No entanto, todos os estudos clínicos baseados em 
terapias anti-angiogénicas têm-se revelado ineficazes no tratamento de 
pacientes com cancro da mama. Uma vez que a Angiopoietina 2 (ANG-2), 
outro fator de crescimento vascular, tem sido reportada como responsável 
pela resistência a terapias baseadas no bloqueio de função do VEGF, é 
possível que pacientes com cancro da mama beneficiem de uma estratégia 
terapêutica que neutralize simultaneamente ANG-2 e VEGF-A. De facto, 
através do uso de um anticorpo ‘biespecífico’, capaz de neutralizar tanto 
ANG-2 como VEGF-A e denominado A2V, observou-se uma forte inibição da 
progressão tumoral e aumento da sobrevivência num modelo pré-clínico de 
cancro da mama agressivo, baseado em ratinhos transgénicos e denominado 
MMTV-PyMT. Consistentemente, esta terapia levou ao aumento de necrose 
tumoral e a uma drástica redução na densidade vascular, sem evidência de 
revascularização ou resistência à terapia. A administração de A2V induziu 
ainda o aumento da associação entre células perivasculares (‘pericytes’) e 
células endoteliais dos restantes vasos sanguíneos tumorais, favorecendo a 
maturação e normalização vascular, o que facilita o desenvolvimento de um 
microambiente que suporta respostas imunológicas. Estes resultados 
sugeriam assim que imunoterapia em cancro da mama poderia beneficiar da 
combinação com A2V, tendo-se por conseguinte combinado o anticorpo A2V 
com o anticorpo agonista de CD40 (FGK45), no modelo ortotópico de MMTV-
PyMT. Esta terapia induziu uma notável inibição do crescimento tumoral, com 
obtenção de casos estáveis, e aumento adicional de necrose tumoral. 
Observou-se ainda o aumento de infiltração de células CD8+ após terapia 
com FGK45, quer isoladamente ou em combinação com A2V, e uma 
correlação entre a extensão da inibição do tumor e o aumento da infiltração 
tumoral por células CD8+. Isto sugere que o influxo de células CD8+ nos 
tumores tratados com A2V e FGK45 foi o principal responsável pelas 
notáveis respostas anti-tumorais observadas. Em resumo, estes resultados 
apontam para uma sinergia entre a neutralização simultânea de ANG-
2/VEGF-A e imunoterapia baseada em agonistas do recetor CD40, no 
modelo pré-clínico de cancro da mama MMTV-PyMT. Esta abordagem 
combinatória pode beneficiar pacientes com cancro da mama, por isso, mais 
estudos são necessários para explorar os mecanismos subjacentes à 
atividade cooperativa da terapia anti-angiogénica e a imunoterapia. 
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 Breast cancer, angiogenesis, VEGF-A, ANG-2, anti-angiogenic therapy, 
cancer immunoediting, CD40 agonistic-mediated immunotherapy. 
Angiogenesis is crucial for breast cancer growth, progression and 
dissemination, making it a promising therapeutic target. Given the dominant 
role of Vascular Endothelial Growth Factor (VEGF) signaling in tumor 
angiogenesis, the majority of clinical studies with anti-angiogenic therapies in 
breast cancer were based on VEGF blockade. However, lack of clinical 
efficacy was observed in all clinical studies with antiangiogenic therapies for 
breast cancer. Since angiopoietin 2 (ANG-2) has been reported to induce 
therapeutic resistance after VEGF-targeted therapies, breast cancer patients 
may benefit from a therapeutic strategy that simultaneously blocks ANG-2 and 
VEGF-A. Indeed, using the bispecific ANG-2/VEGF-A targeting antibody 
(A2V), durable inhibition of tumor progression, as well as increased survival, 
could be observed after dual ANG-2/VEGF-A blockade in the aggressive 
mouse model of breast cancer, the MMTV-PyMT transgenic mouse. 
Consistent with tumor inhibition, increased tumor necrosis and a drastic 
reduction of vascular density was observed after A2V therapy, with little 
evidence of tumor revascularization or resistance to therapy. Moreover, A2V 
led to increased perivascular coverage of the remaining tumor blood vessels, 
favoring vascular normalization, which is known to facilitate the development 
of an immunosupportive microenvironment. These findings suggested that 
breast cancer immunotherapy may benefit from the combination with A2V. 
Therefore the A2V mAb was combined with a CD40 agonistic antibody 
(FGK45). The combined therapeutic approach led to remarkable tumor growth 
inhibition in an orthotopic MMTV-PyMT model, with the achievement of cases 
of stable disease and further increase in tumor necrosis. Increased infiltration 
of CD8+ cells after FGK45 therapy, either alone or in combination with A2V, 
could also be observed. Of note, a correlation between the extent of tumor 
inhibition and increased tumor infiltration by CD8+ cells was detected, 
suggesting that the influx of CD8+ cells in the combination therapy-treated 
tumors was responsible for the remarkable anti-tumor responses observed. In 
summary, these results point to a significant synergistic activity of anti-ANG-
2/VEGF-A and CD40 agonistic therapy in the MMTV-PyMT model of breast 
carcinoma. This combinatorial approach may benefit breast cancer patients, 
so further studies that explore the mechanistic bases of the cooperative 
activity of antiangiogenic and immunostimulatory therapy are warranted. 
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1. Introduction  
 
Cancer is a complex disease whose development occurs in a multistep manner, each 
step reflecting a genetic alteration, driving the progressive transformation of normal cells 
into highly malignant derivatives (1). Throughout these transformations the cells acquire 
cancer hallmark capabilities that enable them to survive, proliferate and disseminate. 
Cancer is a dynamic system that continuously evolves by altering and recruiting the 
surrounding host non-cancer cells (endothelial cells, pericytes, cancer-associated 
fibroblasts and bone marrow-derived stromal cells) in order to create a more permissive 
milieu for its growth and progression, named tumor microenvironment (2). Indeed, it is 
known that the composition of the tumor stroma influences the prognosis of several forms 
of cancer, including breast cancer (3), and the clinical outcome of cancer treatments. Thus, 
therapies targeting these cells can impair the tumor growth and dissemination, prolonging 
the survival of cancer patients.  
In this project, an innovative therapeutic approach, aiming to simultaneously target 
tumor angiogenesis and the tumor immune response, is discussed in mouse models of 
breast cancer.  
 
1.1. Breast cancer 
 
Breast cancer can be described as a heterogeneous disease encompassing 
multiple subgroups with differing molecular signatures, prognoses, and responses to 
therapies (4). Despite the scientific advances in the past several decades, breast cancer is 
the second leading cause of cancer related death in women (5).  Among european women, 
the breast cancer alone accounts for 28,8% of all cancer cases, with a total of 464 000 
incidence cases in 2012, of which 131 000 cases resulted in death, corresponding to 16,8% 
of the cancer-related deaths in women (6). 
The mammary gland can undergo multiples cycles of proliferation, lactation and 
involution, due to the presence of a population of mammary stem cells, capable of self-
renewal, lineage commitment and epithelial differentiation in both luminal or 
myoepithelial/basal cells (5). The breast cancer driven mutations can either occur in 
mammary stem cells, leading to the establishment of cancer-stem cells (CSCs), in lineage 
committed progenitor cells or even in differentiated cells, giving rise to different breast 
cancer subtypes (7).  
Perou et al. were the firsts to describe the distinct molecular subtypes of breast cancer 
using microarray-based gene expression analysis (8). Six molecular subtypes of breast 
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cancer are known: luminal A, luminal B, HER2-enriched, basal-like, normal breast and 
claudin-low. Each subtype exhibits distinct cell signatures (with mesenchymal, luminal or 
basal signatures), with the expression of different proliferation-related genes and steroid 
and/or growth factor receptors, accordingly to the specific mutation occurring in each 
subtype (9, 10). More importantly, each subtype reveals different responses to therapy 
and distinct prognoses, with the basal-like/triple-negative subtype having the shortest 
survival (9).  
For many years, the medical treatment of breast cancer relied solely on chemotherapy, 
where the combined action of paclitaxel and doxorubicin had the best responses (30%-
50%) (10, 11). However, the different subtypes of breast cancer respond differently to 
chemotherapy, with the basal-like and HER2-enriched subtypes being more sensitive to 
paclitaxel and doxorubicin, in a neoadjuvant setting, than the luminal cancers (12). 
Therefore over the past twenty years, treatment has evolved to a more target-directed 
approach. From a clinical/therapeutic point of view, breast cancer can be subdivided into 3 
major subtypes: (a) tumors expressing Hormone Receptors (HR), namely the Estrogen (ER) 
and Progesterone (PR) nuclear receptors, known as HR+ breast cancer (60%); (b) tumors 
with overexpression of the Human Epidermal growth factor Receptor 2 (HER2), a tyrosine 
kinase receptor, HER2+ breast cancer (20%); and (c) the triple negative tumors, that lack 
the expression of ER, PR and HER2 (20%) (13).   
The estrogen receptor antagonist tamoxifen (Nolvadex®), as a single agent, has been 
the gold standard treatment for HR+ breast cancers, achieving a 26% mortality reduction in 
patients treated with tamoxifen for 5 years (14). Other estrogen-focused therapies, based 
on the administration of aromatase inhibitors (AIs) that prevent the synthesis of 
estrogen, or the ER-degrading agent Fulvestran (Faslodex®), are able to extend the 
survival in breast cancer patients (15). Nonetheless, up to 50% of patients with HR+ 
cancer develops resistance to HR-therapies, as a result of a cross talk between ER and 
HER2, leading to HER2 overexpression or the alternative activation of its downstream 
pathway, the PI3K/Akt/mTOR pathway (4). This resistance can be partially overcome by 
combining anti-estrogen and anti-HER2 therapies, as showed by the significant 
increased progression free survival when combining anastrazole (Arimidex®), an aromatase 
inhibitor, plus the anti-HER2 monoclonal antibody (mAb) trastuzumab in such cases 
(progression free survival (PFS) of 4.8 months vs. 2.4 with anastrazole alone) (16).  
The first commercially available HER2 targeting agent was the mAb trastuzumab 
(Herceptin®), approved by the US Food and Drug Administration (FDA) in 1998 for the 
treatment of HER2+ breast cancer (17). Trastuzumab established a new treatment 
paradigm for HER2+ breast cancer and it is still the standard first line treatment for this 
subtype of breast cancer, in combination with chemotherapy or as a single agent (18).  
When combined with chemotherapy, trastuzumab increases the overall response rate and 
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improves the median survival time by approximately 25%, compared with chemotherapy 
alone (19). Other anti-HER2 therapeutic strategies include the dual HER1/HER2 tyrosine 
kinase inhibitor (TKI) lapatinib (Tyverb®), or pertuzumab (Perjeta®), an mAb that binds to a 
different domain of the extracellular portion of the HER2 than trastuzumab, inhibiting 
HER2 dimerization (13). However, just like the HR+ cancer subtype, resistance to anti-HER2 
agents may occur as a result of activating PIK3CA mutations or loss of function of the 
phosphatase PTEN, leading to aberrant activation of the PI3K/Akt/mTOR downstream 
pathway (20). PI3K/Akt/mTOR target approaches may improve the responses of these 
patients, and indeed everolimus (Afinitor®), an mTOR inhibitor, seems to restore the 
sensitivity to anti-HER2 agents: a phase I study combining everolimus, trastuzumab and 
paclitaxel in trastuzumab-pretreated patients with HER2-overexpressing breast cancer, 
showed an overall response rate (ORR) of 44%, with controlled disease for six months in 
74% of the patients (21).  
The Triple Negative Breast Cancer (TNBC), due to the lack of expression of the 3 key 
receptors in breast cancer (ER, PR and HER2), cannot be target with the therapies 
mentioned above (22).  Instead TNBC, with high incidence of BRCA mutations, can be 
target using PARP (Poly ADP Ribose Polymerase) inhibitors. Impairing the remaining DNA 
repair machinery within BRCA-deficient cancer cells using PARP inhibition results in 
synthetic lethality, due to chromosomal instability, cell-cycle arrest and apoptosis. In fact, a 
study with the PARP1 inhibitor olaparib (AstraZeneca®), as a single agent, led to ORR of 
41% in BRCA mutated breast cancer patients, without significant toxicity (23). EGFR or 
HER1, also expressed in this type of breast cancer, can be target by using the anti-EGFR 
monoclonal antibody cetuximab (Erbitux®), which has a limited activity as a single agent, 
but can double the antitumor activity of platinum salts, like cisplatin (24).  
As a result of these novel target therapies, over the past two decades breast cancer 
mortality rates have decline by approximately 30% (25). Nevertheless, the development of 
resistance to all these therapies is an ongoing challenge, where the development of new, 
non-toxic therapies are greatly needed. A study developed by Finak et al. (2008) (26) 
disclosed that distinct gene expression signatures in breast tumor stroma reflected 
different clinical outcomes independently of the tumor subtype. They revealed that tumor 
stroma samples with overexpression of cytotoxic T cell and natural killer (NK) cell markers 
displayed a good clinical outcome, while samples with increased hypoxic and angiogenic 
responses, as well as a decrease in chemokines that stimulate NK cell migration (CXCL14) 
and mediate prosurvival signals in T lymphocytes (GIMAP5), displayed a poor outcome. 
This study strongly suggests that breast tumor stroma has a crucial role in disease 
progression and clinical outcome. Therefore anti-angiogenic and immune therapies, 
addressed hereafter, appear to be a promising approach for the treatment of breast 
cancer.  
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1.2. Angiogenesis and anti-angiogenic therapy  
 
Blood vessels supply the normal tissues with oxygen and nutrients, while disposing of 
metabolic waste and carbon dioxide (27). Although the formation of blood vessels is 
required for physiological processes, such as pre/postnatal development and tissue repair, 
they are also required by tumors to allow their survival and proliferation (28).   
Angiogenesis, the sprouting of new blood vessels from preexisting ones, plays a rate 
limiting role in tumor growth. Although cancer cells can recruit bone marrow derived cells 
(BMDCs), which include endothelial progenitor cells capable of inducing vasculogenesis (de 
novo formation of blood vessels) (29), without angiogenesis the rate of tumor cell 
proliferation reaches the equilibrium with the rate of cell death, and the tumor enters in a 
‘dormant phenotype’ (30). 
In adult tissues the vasculature becomes quiescent, as a result of a balance between 
pro- and anti-angiogenic factors. The most relevant pro-angiogenic factors are the Vascular 
Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), Angiopoietins (ANG-1 
and ANG-2), Platelet-Derived Growth Factor (PDGF) and IL-8. Conversely, Thrombospondin 
1 (TSP1), Endostatin and Angiostatin are some of the factors that negatively regulate 
angiogenesis (31). In quiescent tissues angiogenesis is only turned on, transiently, to allow 
certain physiological processes such as wound repair. However, during tumorigenesis, both 
the tumor and its stroma cells secret an excess of pro-angiogenic factors tipping the 
balance in favor of angiogenesis. This process known as the ‘Angiogenic Switch’, where 
angiogenesis is persistently activated, allows continuous sprouting of new blood vessels. 
Induced early during tumorigenesis, the angiogenic switch is required for tumor 
progression to malignancy, allowing the tumor to growth and become more likely to 
metastasize (2, 32). 
 
1.2.1. Angiogenesis regulation 
The sprouting and maintenance of blood vessels is a complex process, tightly regulated 
by multiple pathways. Given the ancestral function of vessels to supply oxygen, endothelial 
cells (ECs) are equipped with oxygen sensors and hypoxia-inducible factors, allowing the 
vessels to readjust their shape and blood flow according to the oxygen levels (33). 
Quiescent mature ECs form a monolayer of cells, interconnected by V-cadherin and claudin 
molecules, and covered by pericytes, a contact stabilized by N-cadherin molecules. In this 
quiescent context, the ECs and the pericytes share a common basement membrane (27). 
When the levels of oxygen drop, hypoxic or inflammatory cells release VEGF and other 
angiogenic signals, creating a gradient of pro-angiogenic factors and chemotactic signals 
that promote angiogenic sprouting by guiding filopodial extension from specialized 
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endothelial cells located at the tips of the vascular sprouts, named ‘tip cells’, ensuring 
branch formation. This process requires proteolytic degradation of the basement 
membrane (mediated by matrix metalloproteinases (MMPs)), pericyte detachment (in 
response to ANG-2) and loosening of endothelial cell junctions. The ‘tip cell’ is then 
followed by the less mobile proliferating ‘stalk cells’, allowing elongation and lumen 
formation (34). Ultimately neighboring branches fuse and a perfused blood vessel is 
formed. However, for the vessel to become functional, it must become mature and stable. 
For this purpose signals such as PDGF, ANG-1 and NOTCH support pericyte coverage; 
protease inhibitors cause the deposition of the basement membrane, and junctions are re-
established (35). 
The constitutive activated angiogenesis and overexpression of different VEGF isoforms 
by the tumor cells leads to an aberrant and dysregulated tumor vascularity, characterized 
by a variable diameter, irregular shapes and chaotic blood flow (2, 32). Tumor vessels also 
fail to mature, due to persistent angiogenic stimulus, presenting scarce and loosely 
associated pericytes with incomplete basement membranes, which increases vessel 
leakiness (36). All together, these features lead to poor blood perfusion and high 
interstitial fluid pressure. Consequently, in spite of the tumor vasculature development, 
tumors retain a certain level of hypoxia, resulting in the continuous overproduction of 
VEGF and persistent aggravation of the abnormal tumor vessel phenotype (37).  
Although regulated by multiple pathways, there is a strong dominancy of the VEGF 
pathway in angiogenesis, as shown by the embryonic lethality in mice with loss of a single 
Vegf allele (38, 39). There is also an important role played by the Angiopoetin-Tie signaling 
pathway in vessel maturation and quiescence, verified by the embryonic lethality in ANG-1 
or TIE-2 knockout mice (40, 41). Since both of these pathways can regulate different 
aspects of blood vessel growth they are briefly explained below.   
 
 1.2.1.1. The VEGF pathway 
The VEGF, also known as VEGF-A, is an endothelial cell-specific mitogen, first isolated 
from the supernatant of bovine pituitary cells by Ferrara and Henzel in 1989 (42). The 
VEGF family includes the VEGF-A, the Placenta Growth Factor (PLGF), the VEGF-B, C and D 
(43).   
The human VEGF-A, known to remarkably regulate angiogenesis in a predominant 
fashion, is encoded by the VEGF-A gene, organized in eight exons. Alternative exon splicing 
generates several isoforms of the VEGF-A, differing in their ability to bind heparin (44). The 
VEGF 165, an heparin binding homodimeric glycoprotein, is the most physiologically 
relevant isoform (45). After secretion, a significant fraction of this molecule remains bound 
to the extracellular matrix (ECM), through the heparin-binding sites. Therefore, ECM 
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proteolysis by MMPs plays a key role in regulating vascular patterning in vivo by increasing 
the release, and consequently the bioavailability, of VEGF from the ECM (46). This process 
is thought to be responsible for the angiogenic switch in some tumors (47).  
Besides the well-documented action in promoting the growth of ECs, the VEGF-A is also 
a homeostatic survival factor for these cells, an activity mediated by the 
phosphatidylinositol 3-kinase (PI3K)/Akt pathway (48). Akt activation in ECs is dependent 
on matrix attachment: integrin molecules when attached to the ECM can activate PI3K 
through the focal adhesion kinase (FAK). This leads to Akt activation and its downstream 
targets involved in apoptosis regulation, such as Bad and FKHR family of forkhead 
transcription factors, resulting in EC survival (49).  
Although ECs are the primary targets of VEGF-A, BMDCs can also respond to its 
mitogenic/survival effects, including monocytes and their precursors (Hematopoietic Stem 
Cells – HSCs) (45). Furthermore the VEGF-A is also known as a vascular permeability factor 
and potential pro-metastatic factor, based on its ability to induce the loosening of the cell-
cell contacts, facilitating the intravasion/extravasion of tumor cells (50).  
Hypoxia is known to be a major inducer of VEGF-A gene transcription, a process 
mediated by the hypoxia-inducible factor 1 (HIF-1) (51). However VEGF-A gene expression 
can also be upregulated by oncogene signaling (52), and by the expression of several 
growth factors and inflammatory cytokines (43).  
The VEGF-A effects are mediated by two receptor tyrosine kinases (RTKs): the VEGFR-1, 
also known as Flt-1, and the VEGFR-2, also known as Flk-1 (Figure 1) (53, 54). In addition 
VEGF-A can also bind to its co-receptors neuropilins (55). Another member of the VEGFR 
family is the VEGFR-3 (Flt-4), however it’s not a receptor for the VEGF-A. Instead VEGFR-3 
regulates lymphangiogenesis upon the binding to VEGF-C and D (56). 
Although VEGFR-1 was the first RTK to be identified as a VEGF-A receptor, current data 
show that VEGFR-2 is the major mediator of the mitogenic, angiogenic and survival effects 
of VEGF-A (57). Unlike the binding of VEGF-A to VEGFR-2, the VEGFR-1 undergoes weak 
tyrosine autophosphorylation upon binding of VEGF-A, suggesting that this receptor acts as 
a ‘decoy receptor’ for the VEGF-A/VEGFR-2 signaling (58). In fact, at least during early 
development, the VEGFR-1 is a negative regulator of the VEGF-A activity, by preventing its 
interaction to VEGFR-2 (partially due to sequestering of VEGF-A by the soluble form of the 
VEGFR-1 (59)) (60). Nevertheless, the tyrosine kinase domain of VEGFR-1 is required for 
the migration of monocytes in response to VEGF-A (chemotaxis of monocytes) (61), and its 
activation by PLGF is able to reconstitute hematopoiesis by recruiting VEGFR-1 positive 
HSCs (62). Furthermore, VEGFR-1 can also induce the production of MMPs, which in a 
tumor context can facilitate metastasis (63).  
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VEGFR-2 undergoes dimerization and strong ligand-dependent tyrosine 
phosphorylation, leading to phosphorylation of several proteins involved in mitogenic and 
pro-survival pathways (64): VEGF-A/VEGFR-2 signaling leads to EC growth through 
activation of the Raf-Mek-Erk pathway (65), and induces their survival by activating the 
PI3K-Akt pathway (48).  
 
Figure 1. The VEGF pathway (Adapted from Ferrara et al., Nature Medicine, 2003 (45)) 
 
Although essential for several physiologic processes, such as normal embryonic 
vasculogenesis/angiogenesis (39), endochondral bone formation (66) and the ovarian cycle 
(67), VEGF-A mRNA expression is present in many human tumors, allowing the formation 
of the tumor vasculature (68). 
 
1.2.1.2. The Angiopoietin-TIE-2 pathway 
 
The angiopoietin (ANG)-Tie system was the second endothelial-specific receptor 
tyrosine kinase signaling system identified (69). It regulates the later steps of the 
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angiogenic cascade, related to vessel maturation, and functions as a key regulator of adult 
vascular homeostasis (27, 70).  
This system consists of two RTKs, TIE-1 and TIE-2, and three ligands, ANG-1, ANG-2 and 
ANG-3/4. TIE receptors are single transmembrane RTKs with an N-terminal ANG-binding 
domain and a C-terminal tyrosine kinase domain, mainly expressed on ECs and 
hematopoietic cells (70, 71). All angiopoietins bind to TIE-2, while TIE-1 is as an orphan 
receptor. However, TIE-1 interacts with TIE-2, and both can translocate to endothelial cell-
cell contacts upon angiopoietins stimulation (mainly ANG-1), supporting EC junction (72). 
ANGs are cytokines consisting of an N-terminal coiled-coil domain and a C-terminal 
fibrinogen-like domain, responsible for the binding to TIE-2 receptor. Electron microscopy 
showed that both ANG-1 and ANG-2 bind to TIE-2 as multimers (70). 
ANG-1 was initially identified as an agonistic TIE-2 ligand, maintaining the resting EC 
phenotype (71), while ANG-2 was identified as an antagonist of the ANG-1-TIE-2 signaling 
pathway (73), even though they bind with similar affinity and in the same domain (74). 
However, it is now known that ANG-2 can act as a partial TIE-2 agonist in a context-
dependent manner (70). ANG-1 is mainly expressed by perivascular cells (pericytes and 
smooth muscle cells) acting on TIE-2 receptors of ECs through a paracrine manner, 
whereas ANG-2, produced by activated/sprouting ECs, acts in an autocrine manner (75). 
ANG-2 is stored by ECs in specialized endothelial storage granules, called Weibel-Palade 
bodies, and released upon vascular remodeling, promoting angiogenesis likely by 
antagonizing ANG-1-mediated EC quiescence (76).  
The binding of ANG-1 to TIE-2 leads to strong phosphorylation of the tyrosine kinase 
domain, leading to the recruitment of adaptor proteins, such as PI3K, which results in the 
activation of the AKT pathway (77). In turn, AKT signaling modulates  survival and apoptotic 
pathways, leading to EC survival and maintenance (Figure 2) (70).  Furthermore, ANG-1-
TIE-2 signaling results in a negative feedback loop on EC ANG-2 production, since AKT 
signaling inactivates the transcription factor FoXo1, which targets ANG-2 (78). Beside the 
well described effect on vascular homeostasis, the ANG-1-TIE-2 signaling in non-resting ECs 
can stimulate their migration, an effect mediated by phosphorylation of focal adhesion 
kinase (FAK) (70). ANG-1-activated TIE-2 can also decrease permeability and inflammation, 
by inhibiting the nuclear factor-κB (NF-κB) (79), and induce maturation of blood vessels, by 
stimulating the migration of pericytes towards ECs (thought to be mediated by heparin-
binding epidermal growth factor, hepatocyte growth factor and serotonin) (70). 
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Figure 2. The ANG-TIE pathway (adapted from Huang et al., Nat. Rev. Cancer, 2010 (75)) 
 
It is remarkable how ANG-1 and ANG-2 can induce opposite effects (vascular 
stabilization or angiogenesis, respectively) via the same TIE-2 receptor. Current studies 
suggest that ANGs can alter the subcellular localization of TIE-2 in a distinct manner, 
enabling different responses of the TIE-2 signaling: while ANG-1 leads to TIE-2 clustering 
and activation at inter-endothelial cell-cell junctions, mediating cell–cell adhesion, 
antipermeability and EC survival; ANG-2 binds to TIE-2 located at EC-ECM contact sites, 
antagonizing ANG-1 signaling and enhancing EC responsiveness to exogenous cytokines, 
such as VEGF (72). Furthermore, several reports suggest that ANGs can bind to integrins, 
which in turn can modulate ANG-1 and ANG-2 specific signals (75).  
In quiescent tissues ANG-2 levels are low, favoring the ANG-1-TIE-2 signaling. However, 
during tumor angiogenesis ANG-2 expression is upregulated, favoring instead the ANG-2-
TIE-2 signaling (70). In such cases the acute release of ANG-2 from activated ECs results in 
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pericyte detachment with consequent exposure of ECs to pro-angiogenic signals, favoring 
tumor angiogenesis (76). Tumor-associated ANG-2 can also promote angiogenesis by 
recruiting a population of hematopoietic TIE-2 expressing cells, first described by De Palma 
and co-workers: the TIE-2-Expressing Monocytes/Macrophages (TEMs) (80). Although 
weakly expressed by circulating resident monocytes, TIE-2 is upregulated in a subset of 
perivascular tumor-associated macrophages (TAMs), which display a distinct gene 
expression signature consistent with enhanced pro-angiogenic activity, when compared 
with TIE-2 negative TAMs (76, 81).  
 
1.2.2. The angiogenic switch in breast cancer 
In breast cancer, an increased infiltration of macrophages occurs in the nonmalignant 
adenoma stage, preceding the transition to the malignant stages of carcinoma associated 
with the angiogenic switch. This observation suggested that macrophages promote the 
angiogenic switch in breast cancer (82). Indeed, studies performed by Lin and co-workers 
reveled a dramatically delay of the angiogenic switch in mouse models of breast cancer 
upon macrophage depletion (83).  
At a certain point, tumor cells start to produce monocyte chemokines, such as the 
Colony-Stimulating Factor 1 (CSF-1) (Figure 3), recruiting them into the tumor where they 
differentiate into TAMs, often with an alternative (also termed “M2”) polarization 
phenotype (84). These cells are then able to support the tumor progression through 
several mechanisms, including the induction of tumor angiogenesis (85), by producing 
angiogenic growth factors and proteinases, such as VEGF, ANG-2 and MMP-9 (82).  
Furthermore, vessel-associated TAMs, the TIE-2-Expressing Macrophages, can also 
promote the formation of the tumor vasculature, a process mediated by the ANG-2-TIE-2 
signaling (80).  
The tumor-promoting role of these cells in the progression of established tumors might 
explain the correlation between high density of macrophages and poor prognosis observed 
in human breast cancer (86).  
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Figure 3. TAMs as the drivers of breast cancer malignancy (Adapted from Lin and Pollard, 
Cancer Res., 2006 (82)) 
 
1.2.3. Anti-angiogenic therapy 
 
Decades ago Judah Folkman disclosed that without expanding the blood vasculature the 
tumor cannot exceed 2-3mm, and hypothesized that inhibition of angiogenesis would be 
an effective strategy to treat human cancer (87). Since then, an active search for 
angiogenesis inhibitors began and, despite some initial setbacks and negative clinical trial 
results, in 2004 the FDA approved the first anti-angiogenic drug for cancer therapy: the 
VEGF-A neutralizing mAb bevacizumab, as a first-line treatment for metastatic colorectal 
cancer (38). 
 
1.2.3.1. Targeting the VEGF pathway 
Because VEGF plays a central role in tumor angiogenesis, the first angiogenesis 
inhibitors aimed to impair the VEGF-A/VEGFR-2 signaling pathway, with several VEGF 
neutralizing mAbs, and multi-target TKIs already approved for clinical applications (32).   
In 1993 Ferrara and co-workers developed the first anti VEGF-A mAb, a mouse anti-
human antibody named A.4.6.1. They observed a potent inhibitory effect on tumor 
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angiogenesis and growth of several tumor cell lines in nude mice (70% to 90% of tumor 
growth inhibition) (88). Later on, they reported the humanized version of A.4.6.1, termed 
bevacizumab (Avastin©), which binds to and neutralizes all human VEGF-A isoforms and 
bioactive proteolytic fragments, but not to other VEGF ligands (VEGF-B, C or D) (38). 
Bevacizumab is currently approved for the treatment of advanced and metastatic 
colorectal cancer, renal cell cancer, non-small cell lung cancer and glioblastoma 
multiforme (89).  
Besides targeting the VEGF-A, mAb targeting VEGFR-2 were also generated, as the 
DC101 murine antibody (ImClone Systems) (90) and the ramucirumab (Cyramza©) (91). 
The later was recently approved by the FDA for the treatment of gastric or 
gastroesophageal junction adenocarcinoma.  
In addition, small molecule TKIs capable of inhibiting the activity of VEGFRs via ATP-
competitive binding, have also been approved. Besides VEGFR, these TKIs also inhibit the 
Platelet-Derived Growth Factor Receptors (PDGFRs), Flt-3, c-Kit, RAF and RET, suggesting 
that they may have a direct antitumor effect (by inhibiting oncogenic and growth-
promoting kinases) in addition to antiangiogenic functions. Sorafenib (Nexavar©), sunitinib 
(Sutent©) and pazopanib (Votrient©) are TKIs approved for the treatment of human 
cancers (92).  
VEGF inhibitors have been approved by the FDA for the treatment of patients with 
highly advanced malignancies (metastatic setting) or in cases of inoperable diseases (43). 
Because one side effect of blocking VEGF is bleeding complications, anti-VEGF agents are 
not administered to patients before surgery (93).  
 
However, like the majority of anticancer therapies, patients treated with anti-VEGF 
therapies develop resistance, and benefit from the therapy for only a few months 
(adaptive resistance) or don’t benefit at all (intrinsic resistance) (29). Indeed, in several 
mouse tumor models, although VEGF inhibition results in reduced angiogenesis and tumor 
growth, tumors usually re-vascularize upon prolonged treatment (94). In 2008 Bergers and 
Hanahan reviewed the mechanisms of resistance to anti-VEGF therapy, which include the 
upregulation of alternative proangiogenic growth factors (as ANG-2), the increased 
coverage of blood vessels by perivascular cells, the increased recruitment of BMDCs and 
increased tumor cell invasiveness (29). 
 
 Compelling data have shown that ANG-2 is responsible for inducing tumor resistance to 
anti-VEGF therapy: upon VEGF blockade there is an overexpression of ANG-2, allowing the 
tumor vasculature to become VEGF independent. Preclinical studies, conducted by 
Rigamonti and co-workers, have shown an upregulation of ANG-2 at both transcript and 
protein levels upon prolonged VEGFR-2 blockade in the RIP1-Tag2 pancreatic tumor model 
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(95). They also demonstrated that the resistance to VEGF blockade could be reversed by 
ANG-2 neutralization. These results, as well as previous studies (96-98), suggest that 
targeting of ANG-2-TIE-2 and VEGF-VEGFR2 signaling pathways represent a promising 
therapeutic approach to avoid the induction of adaptive resistance and obtain a durable 
antiangiogenic effect. 
 
 
1.2.3.2. Targeting the ANG-TIE pathway 
Higher ANG-2/ANG-1 ratio, when compared with normal tissues, correlates with poor 
prognosis in many human cancers, including myeloid leukaemia (99), breast cancer (100), 
neuroendocrine cancers (101), prostate cancer (102), and many others (103-106). 
Although the effect of targeting ANGs is context dependent (107), higher ANG-2/ANG-1 
ratio also correlates with increased angiogenesis, invasion and metastasis, making the 
antitumor and antiangiogenic benefits of targeting ANG-2 evident (75). 
Several studies have demonstrated that specific inhibition of ANG-2 induces durable 
tumor growth inhibition, vascular regression with normalization of the remaining blood 
vessels, and suppression of metastatic spread (97, 98, 108). Furthermore, blocking ANG-2 
also impedes TIE-2 upregulation by TAM/myeloid cells and their association with tumor 
blood vessels (98, 108), suggesting that targeting ANG-2-TIE-2 axis can also inhibit tumor 
angiogenesis indirectly, by impairing the pro-angiogenic functions of TEMs (besides directly 
targeting the autocrine signaling on ECs). According to these data, ANG-2 blockade 
represents a promising antiangiogenic therapy, capable not only of blocking angiogenesis 
and metastasis, but also impairing the recruitment of myeloid cells (109), known to allow 
tumor recovery after antiangiogenic therapy (29).   
Specific inhibitors of ANG-2 have been developed over the past few years, including a 
human anti-ANG-2 mAb, termed MEDI-3617 (3.19.3) (97, 98), or a ANG-2 CovX-Body, 
composed of a peptide coupled to a monoclonal antibody via covalent linker, termed PF-
4856884 (also known as CVX-060) (108). Recently the CVX-060 was evaluated, in 
combination with sunitinib, in a phase I/II trial in patients with metastatic renal cell cancer 
and solid tumors. Analysis demonstrated safety of CVX-060, however no increased overall 
survival (OS) was observed by combining CVX-060 with sunitinib (110). Additionally a 
peptibody targeting both ANG-1 and ANG-2, AMG-386, has been developed and tested in 
several clinical trials, with demonstrated tolerability but no clinical efficacy (111-113). The 
aforementioned molecules mediate their effects by preventing ANG-2 binding to TIE-2 
receptor, however the TIE-2 receptor can also be targeted by kinase inhibitors, such as the 
CEP-11981 and the CE-245677 (75). 
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1.2.3.3. Co-targeting the VEGF and ANG-TIE pathways 
High levels of VEGF-A and ANG-2 correlate with worse prognosis in several human 
cancers, including breast cancer, when compared with cancers expressing high levels of 
either alone (114). These results, together with the fact that ANG-2 might be a key player 
in the induction of adaptive resistance to anti-VEGF therapy, suggest that co-targeting 
ANG-2 and VEGF-A could provide a better antitumor effect, when compared to 
monotherapies.  
In order to test that hypothesis several bi-specific drugs, targeting both VEGF-A and 
ANG-2, have been developed, such as the bi-functional CovX-Body CVX-241 (75), a 
chimeric decoy receptor DAAP (double antiangiogenic protein) (115), and the ANG-2-
VEGF-A (A2V) CrossMab, a bispecific human IgG1 antibody capable of blocking VEGF-A and 
ANG-2 simultaneously (116).    
A2V crossmab, produced by Kienast and co-workers, is composed of an arm based on 
bevacizumab (Avastin©), and another based on LCO6, an anti-ANG-2 human IgG1 antibody 
(117). The authors tested the A2V crossmab in a panel of orthotopic and subcutaneous 
mouse tumors and patients or cell line-derived human tumor xenografts, especially at later 
stages of tumor development, using LCO6 (117), bevacizumab (Avastin©) or B20-4.1 (an 
anti-VEGF-A mAb) (118) as monotherapies. They found that simultaneously blocking VEGF-
A and ANG-2 had addictive effects on the inhibition of advanced tumor growth, 
angiogenesis and metastasis, when compared to the monotherapies. A2V crossmab was 
also able to target angiogenic escape pathways described in the clinic, upon anti-VEGF 
monotherapy, preventing tumor revascularization (116).  
ANG-2 inhibition reduced tumor vessel sprouting, whereas VEGF-A inhibition induced 
vessel regression, significantly decreasing tumor vasculature (96). Furthermore, by 
blocking ANG-2, the effects mediated by ANG-1 are potentiated, inducing accumulation of 
adhesion molecules in cell–cell junctions and increasing pericyte coverage (107). As a 
result the remaining abnormal tumor blood vessels become normalized, slowing down 
tumor invasiveness and dissemination/metastasis and increasing the tumor responses to 
other therapies, such as chemotherapy (due to decrease leakage) (119).  
 
1.2.4. Antiangiogenic therapy in breast cancer 
Bevacizumab was the first antiangiogenic therapy to be evaluated in breast cancer (4). 
In a randomized phase III clinical trial (E2100) including mainly HER-2 negative patients, the 
efficacy of paclitaxel alone vs bevacizumab plus paclitaxel was evaluated. Analysis revealed 
an increased Response Rate (RR) (21 versus 37%, P < 0.001) and median PFS (25.2 versus 
26.7 months, P = 0.16), with the addition of bevacizumab (120). These results led to the 
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approval of bevacizumab for HER2-negative metastatic breast cancer in combination with 
paclitaxel, in 2008 by the FDA (121). However, subsequent studies with bevacizumab and 
other chemotherapies demonstrated similar improvements in PFS but failed to show an OS 
advantage (122, 123), which led the FDA to recommend withdraw of bevacizumab for 
breast cancer in 2010 (27). Both the TKIs sunitinib and sorafenib have been evaluated in 
clinical trials (124, 125), but they didn’t receive the approval for the treatment of breast 
cancer.  
Because high levels of ANG-2 correlate with poor prognosis in breast cancer (100), 
agents that target ANG-2 were also evaluated, including a phase II placebo-controlled trial 
in HER2-negative metastatic breast cancer comparing the efficacy of paclitaxel plus AMG 
386 versus paclitaxel plus bevacizumab versus paclitaxel in combination with both drugs. In 
this study, completed in January 2015, blocking ANG-2 showed no apparent prolongation 
of PFS, compared to the controls (126).  
So far there is a lack of successful antiangiogenic therapies in breast cancer, with no 
prolonged OS in the clinical trials.  
 
1.3. The tumor immune environment and immunotherapy  
 
As previously stated, the host immune cells are also recruited to the tumor 
microenvironment, where they have the ability to recognize and destroy the cancer cells, a 
process known as “cancer immunosurveillance” (127-129). However, tumors can develop 
under the presence of a functional immune system, suggesting that cancer cells are able to 
edit the immune system, a process called “cancer immunoediting” (130).  
1.3.1. Cancer immunoediting  
According to Gavin P. Dunn and co-workers, cancer immunoediting better describes 
the dual role of the immune system in cancer (“host-protective” or “tumor-promoting”), 
and consists of 3 distinct phases: elimination, equilibrium and escape (Figure 4) (131).  
Elimination: as described by the immunosurveillance theory, during the elimination 
phase the innate and adaptive immune system can detect and destroy the cancer cells, 
functioning as an extrinsic tumor suppressor (132). Several mechanisms can lead to 
activation of innate immune cells, including the tumor release of type I Interferon (IFN), 
which activates dendritic cells (DCs), or the binding of stress ligands expressed on the 
surface of tumor cells to receptors of antigen presenting cells (APCs), leading to release of 
pro-inflammatory cytokines (133).   
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Figure 4. The three steps of tumor immunoediting (Adapted from Schreiber et al., Science, 
2011 (133)) 
 
Besides the activation of the innate system, the adaptive system is also known to play a 
role in tumor surveillance. Malignant cells express cancer antigens – derived from 
oncogenic viruses, differentiation antigens, epigenetically regulated molecules or 
carcinogenic mutations (134) - which can differentiate them from normal cells (135, 136). 
These cancer antigens, associated with Major Histocompatibility Complex (MHC) class I 
molecules, can be recognized by the T Cell Receptor (TCR) of cytotoxic CD8+ T cells, with 
subsequent activation of an anti-tumor adaptive immune response (137). If this phase is 
successful the tumor is suppressed and not clinically detected (130).  
Equilibrium: this phase occurs when certain tumor cell variants survive the elimination 
phase. In such scenario the host immune system exerts selective pressure on the tumor, 
which is enough to contain it but not sufficient to eliminate it. Even though the adaptive 
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immune system is still able to maintain the tumor in a dormancy state, the tumor immune 
editing takes place in this phase: due to genetic instability new variants of tumor cells 
arise, carrying different mutations with reduced immunogenicity. The equilibrium phase is 
the longest, occurring over a period of many years in humans, and ends when the tumor is 
finally able to escape the immune system (131, 133).  
Escape: due to selective immune pressure, tumor cells acquire the ability to evade 
immune recognition and/or destruction, entering in the escape phase, where the immune 
system is no longer capable of controlling tumor outgrowth (which becomes clinically 
visible) (131, 133).  
 
1.3.1.1. Mechanisms of escape  
Cancer cells can escape the immune system through a series of mechanisms, either by 
reducing immune recognition, or exploiting physiological mechanisms of 
immunosuppression, developed to prevent autoimmunity, in order to impair the host 
antitumor immune response (133). One of these mechanisms is the loss of tumor antigen 
expression by the tumor cells (reviewed in (138)), making them invisible to the immune 
system.  
Tumor cells can also hijack the immune checkpoints for T cell activation (139). Naïve T 
cells require at least two signals to became fully activated (Figure 5): the interaction of 
antigen-MHC complexes with the TCR on the T cells, and the costimulatory signal mediated 
by the binding of B7 molecules (CD80 and CD86) on APCs to the CD28 receptor on the T 
cell surface (140).  
 
Figure 5. T cell activation signals. Inflammatory responses allows APCs to take up the cancer 
antigens, which can be presented to the T cells leading to their activation (Adapted from Sharma 
and Allison, Science, 2015 (141)) 
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However, in order to regulate T cell responses, co-inhibitory molecules are also 
necessary (141). CTLA-4 (Cytotoxic T lymphocyte associate antigen 4) and PD-1 
(Programmed cell death protein 1) are two well-known co-inhibitory molecules (termed 
immune checkpoint modulators) (142-144). Both CTLA-4 and PD-1 are present on the 
membrane of T cells, but while CTLA-4 competes with CD28 for the binding to CD80/86 
(145), PD-1 binds to its ligands PD-L1 (B7-H1) and PD-L2 (146). The activation of a co-
inhibitory pathway leads to attenuation/termination of T cell responses, necessary to 
maintain self-tolerance and modulating the duration and amplitude of T cell response. The 
tumor microenvironment can exploit this process, in order to suppress the antitumor 
immunity, by activating inhibitory receptors on T cells (147, 148).  
Furthermore, cancer cells may evade the immune system by creating an 
immunosuppressive environment (133, 149). In order to do so they can produce 
immunosuppressive molecules, such as Transforming Growth Factor (TGF)-β (150), 
interleukin (IL)-10 or the enzyme indolamine-2,3-dioxygenase (IDO), a mediator of T cell 
activation and regulator of autoimmunity (151). Tumor cells can also recruit pro-tumoral 
infiltrating leukocytes - such as regulatory T cells (Treg), known to inhibit the function of 
cytotoxic T cells (152) -, myeloid-derived suppressor cells (MDSCs) and alternatively 
activated macrophages (M2), which can suppress effective immunity through secretion of 
immunosuppression cytokines, such as IL-10 and TGF-β (153-155).  
All the mechanisms above described allow tumor cells to edit the host immune system 
in their favor, preventing immune responses that would lead to cancer cell dead.   
 
1.3.2. Immunotherapy  
The identification of the immunosuppressive mechanisms present in the tumor 
microenvironment opened the door for the use of immunotherapy for cancer patients. 
Immunotherapy aims to induce an effective immune anti-tumor response by re-editing the 
tumor immunosuppressive microenvironment to the immune surveillance/elimination 
phase (139). Immunotherapy strategies include, among others, vaccination with tumor 
antigens, to elicit strong specific lymphocyte responses, adoptive transfer of tumor-specific 
lymphocytes or inhibition of the mediators of cancer-induced immunosuppression (CTLA-4, 
PD-1, Treg, macrophages, etc) (133).  
 
Special interest has been directed to the immune checkpoint blocking antibodies. 
Immune checkpoint blockade leads to an enhanced activation of cytotoxic T cells, thereby 
priming an anti-tumoral immune response and improving clinical outcomes (139). Indeed, 
ipilimunab (Yervoy©), a mAb against human CTLA-4 led to significant improvement of the 
OR in metastatic melanoma patients, leading to the FDA approval in 2001 (156). Following 
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ipilimunab, several immune checkpoint therapies were developed, including mAb targeting 
the PD-1/PD-L1 axis. The anti-PD-1 antibody MK-3475 (pembrolizumab) led to RR of 38% in 
patients with advanced melanoma in a phase I clinical trial (157), which led to its approval 
by the FDA in September 2014. Nivolumab, another anti-PD-1 antibody was also recently 
approved by the FDA (December 2014) for the treatment of metastatic melanoma, after 
showing an OR of 40% and OS of 73% in a phase III trial, compared with chemotherapy 
(158). 
 
Besides immune checkpoint blockade, immunostimulatory antibodies, such as agonist 
CD40 mAb, are also in clinical development and show a potent anti-tumor effect (159). 
CD40 is a receptor of the Tumor Necrosis Factor (TNF) family and contributes to humoral 
immune responses (160). CD40 is expressed on the surface of several cells, including DCs, 
B lymphocytes, monocytes, ECs, and fibroblasts; while its ligand CD40L, also known as 
CD154, is manly expressed by T lymphocytes and platelets (161, 162).  
 
The binding of CD40L (in a trimeric state) to CD40 causes a conformational change, 
allowing the recruitment of the TNF receptor associated factors (TRAFs) to the CD40 
cytoplasmic tail. This in turn, recruits TRAF associated kinases leading to the activation of 
several signal transduction pathways, including the NF-κB, the p38/MAPK and the c-Jun-
NH2-kinase (JNK) pathways. This allows CD40 to control essential processes such as 
apoptosis, cell cycle, cytokine production and expression of cell surface immune 
modulators (159).  
 
Agonistic CD40 mAb can mount an anti-tumor response through the action of several 
mechanisms (Figure 6).  Physiologically, the interaction between CD40L-expressing CD4+ T 
cells and CD40-expressing DCs leads to maturation and activation of DCs. Activated DCs 
increase the expression of MHC and costimulatory molecules (CD80 and OX40L) and 
production of proinflammatory cytokines (163). This process, known as DC ‘licensing’, is 
required for cytotoxic T cell responses (164). However, agonistic CD40 mAbs can replace 
the activation signal delivered by the CD4+ lymphocytes, allowing increased presentation 
of tumor antigens to CD8 T cells. This results in activation/expansion of cytotoxic T cells 
with subsequent anti-tumor adaptive immune response (165). T cell-independent 
mechanisms, mediating the therapeutic efficacy of agonistic CD40 mAb, have also been 
described. One of this mechanisms is the anti-tumor response achieved by the binding of 
CD40 mAb to CD40-expressing macrophages, which become tumoricidal (166). Some 
tumor cells can also express CD40 (167), including breast cancer cells (168), which upon 
binding to the CD40 mAb are destroyed, even in the absence of immune cells. The CD40-
mediated tumor cell death is due to the activation of apoptotic pathways (169) and has 
been seen in vivo in breast carcinoma (170). Furthermore, cancer antigens released by the 
dying tumor cells, can enhance the activation of cytotoxic T cells, via APCs.  
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Figure 6. Immune dependent and independent mechanisms of action of agonistic CD40 
mAb. (Adapted from Vonderheide and Glennie, Clin Cancer Res, 2013 (171)) 
 
Several CD40 mAbs have been tested in clinical trials, including the mAb CP-870,893 
(Pfizer) (172), dacetuzumab (Seattle Genetics) (173) and lucatumumab (Novartis) (174).  Of 
special interest is the CP-870,893, a fully human agonist CD40 mAb, which displays a 
clinical efficacy in both metastatic pancreatic cancer (175) and advanced solid tumors 
(176). Therefore, agonistic CD40 mAb should be considered for the treatment of cancer.  
 
Other immunotherapy strategies include targeting the immunosuppressive cells 
recruited to the tumor, such as Treg and TAMs, by using anti-CD25 (177) and anti-CSF1R 
mAbs (178), respectively. 
 
1.3.3. Immunotherapy in breast cancer 
Increased numbers of infiltrating CD8+ T cells have been associated with better clinical 
outcomes in patients with breast cancer (179), while worse clinical outcomes were 
observed in the presence of increased Treg (180) and macrophage (181) infiltration. 
Therefore, immune strategies that either increase the infiltration of cytotoxic T cells or 
decrease the infiltration of immunosuppressive cells have been tested in breast cancer.  
 
Blockade of PD-1/PD-L1 pathway has been shown to enhance the response of 
radiotherapy in advanced breast cancer (182), and to be associated with anti-tumor 
activity in a phase I study, with an anti-PD-1 mAb (MDX-1106) as a single agent (183). 
Blockade of CTLA-4 (using tremelimumab and ipilimumab) was also evaluated in breast 
cancer, but with no significant clinical response (184).  
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Additionally, both anti-CD25 antibody-mediated Treg neutralization (185) and anti-
CSF1R-mediated TAM depletion (83, 186) induced a strong anti-tumor immune responses 
in pre-clinical models of breast cancer, which encouraged their evaluation in clinical trials. 
The FDA approved daclizumab, an anti-CD25 mAb, was found to lead to prolonged 
elimination of Treg cells in the peripheral blood of metastatic breast cancer patients taking 
a cancer vaccine, who had a 30% increased survival, compared to those patients taking the 
cancer vaccine alone (187). RG7155 (Roche), a humanized mAb targeting CSF1R, is 
currently being evaluated in a phase I study as a monotherapy and in combination with 
paclitaxel in patients with advanced solid tumors, including an arm with metastatic breast 
cancer (NCT01494688).   
 
All together, these results suggest that therapeutic approaches aiming to adequately 
stimulate a  T cell response in breast cancer, through the mechanisms described above, 
can be a promising strategy to treat breast cancer patients.  
 
1.3.4. Angiogenesis and Immunosuppression  
A substantial number of cells have the ability to promote both immunosuppression and 
angiogenesis including, among others, MDSCs, macrophages and the ECs (reviewed in 
(188)). Of particular interest is the distinct role of the tumor vasculature in editing the 
tumor immunosuppressive microenvironment (188). To do so, tumor endothelial cells can 
either regulate the traffic of leukocytes or directly suppress immune responses (Figure 7).  
 
During a normal inflammatory response, ECs can upregulate chemotactic factors and 
adhesion molecules, such as intercellular adhesion molecule 1 (ICAM1) and vascular cell 
adhesion molecule 1 (VCAM1), enable them to recruit leukocytes and mediate 
diapedesis/extravasation in the target tissue (Figure 7a) (189). However, in a tumor 
microenvironment context, the production of angiogenic factors decreases the expression 
of the adhesion molecules ICAM1 and VCAM 1, thereby decreasing leukocyte 
extravasation, and infiltration in the tumor (Figure 7b) (190, 191). Furthermore, the 
upregulation of certain molecules, such as common lymphatic endothelial and vascular 
endothelial receptor 1 (CLEVER1), can selectively allow the extravasation of Treg cells, 
known to have pro-tumor activity, into the tumor microenvironment (192). 
 
Moreover, tumor ECs can express mediators capable of suppress adaptive immune 
responses (Figure 7c), including the expression of the T cell inhibitory ligands PD-L1 and 
PD-L2 (193), the enzyme IDO (194) or the EC marker CD31, also reported to inhibit T cell 
activation (195). Furthermore, ECs can also express immunosuppressive soluble mediators, 
such as IL-6, IL-10 or the TGF-β (196).   
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Figure 7. Vasculature regulation of immune responses: (a, b) the role in leukocyte trafficking 
and (c) direct immune regulation. (Adapted from Motz and Coukos, Nature, 2011 (188)) 
 
Given the strong immunosuppressive role of ECs in the tumor microenvironment, it is 
possible that immunotherapy might benefit from a co-targeting approach aiming to 
simultaneously target tumor angiogenesis and tumor immunity. Thus, a combined 
antiangiogenic and immunotherapy strategy for the treatment of breast cancer was 
pursued in this study, using the MMTV-PyMT mouse model of breast cancer. 
 
 
1.4. MMTV-PyMT transgenic mouse model of breast cancer 
 
The MMTV-PyMT mouse model is a well-established model to study breast cancer, 
where the Mammary Mouse Tumor Virus (MMTV) promoter drives the mammary gland-
specific expression of the Polyomavirus Middle T antigen (PyMT), resulting in a 
spontaneous development of multifocal mammary tumors (197, 198). Carcinogenesis is 
driven by the activation of specific proto-oncogenes, such as the Shc and the PI3K, as a 
result of the phosphorylation of the membrane-anchored PyMT protein by the Src family 
of TK (198). This model, generated by Guy and colleagues in 1992, is characterized by high 
penetrance (with virtually 100% tumor incidence), short latency (1-6 months) and high 
metastasis incidence (>85%) in lungs and lymph nodes (199). 
Tumorigenesis in this model occurs throughout four stages, with similarities to human 
breast cancer (Figure 8): hyperplasia (at 4-6 weeks of age), adenoma/mammary 
intraepithelial neoplasia (MIN) (8-9 weeks), early (8-12 weeks) and late carcinoma (>10 
weeks) (197). Basement membrane disruption and myoepithelial cell loss, followed by 
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leukocyte and macrophage infiltration occurs even in pre-malignant stage (198). Like in 
human breast cancer, tumor progression to malignancy in the MMTV-PyMT model 
correlates with gradual loss of hormone receptors (ER and PR) and integrin-β1, and 
increased expression of cyclin D1 (197, 200), making it an ideal model to study human 
breast cancer.  
 
Figure 8. The 4 stages of tumor progression in the MMTV-PyMT model, with correspondent 
morphology and biomarkers (Adapted from Fluck and Schaffhausen, Microbiol Mol Biol, 
2009 (198)) 
 
Besides the spontaneous model, orthotopic MMTV-PyMT model can also be generated 
by implanting MMTV-PyMT cells (retrieved from a spontaneous MMTV-PyMT tumor 
bearing mouse) into the mammary fat pad of syngeneic mouse (mouse with identical 
genetic background from the donor mice). This leads to formation of primary tumors with 
possible subsequent formation of metastases. By using syngeneic recipient mice the 
immunologic donor-versus-recipient reaction can be avoid, allowing to evaluate the 
contribution of the immune system to tumor development (201). 
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2. Aims of the Project  
 
2.1. The first aim of the project was to evaluate the anti-tumor effect of dual ANG-
2/VEGF-A blockade in the MMTV-PyMT mouse model of breast cancer. To do so, a novel 
bispecific Ab termed A2V, capable of neutralizing ANG-2 and VEGF-A simultaneously, was 
administered. 
 
Responses to the therapy were evaluated based on: 
- Tumor growth and survival of the mice; 
- Tumor necrosis and fibrosis; 
- Relative tumor vascular area; 
- Perfusion of tumor blood vessels; 
- Tumor hypoxia; 
- Tumor blood vessel coverage. 
 
2.2. The second goal was to assess the possible clinical benefit of co-targeting tumor 
angiogenesis and tumor immunity in the MMTV-PyMT mouse model. For this purpose the 
A2V-based therapy and a CD40-agonistic mAb, termed FGK45, were combined. 
Additionally to the parameters above described, tumor responses were also evaluated 
based on tumor infiltration of T lymphocytes, both by Immunofluorescence staining and 
flow cytometry analysis.  
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3. Materials and Methods  
 
3.1. Mouse tumor models 
FVB/N and transgenic FVB/MMTV-PyMT mice were purchased from Charles River 
Laboratories (L’Arbresle, France). The animals were accommodated in the Animal Facility 
of the École Polytechnique Fédérale de Lausanne (EPFL), under pathogen-free conditions 
with a 12h light/dark schedule, and provided with satisfactory amount of food and water. 
Ethical approval was obtained by the Veterinary Authorities of the Canton Vaud (license 
2577), and all procedures were performed according to the Swiss law.  
To obtain orthotopic MMTV-PyMT tumors, late-stage mammary tumors of a 16-
week old tumor-bearing transgenic MMTV-PyMT female mouse were harvested and 
smashed in a petri dish containing a small volume of a enzymatic solution, prepared by 
diluting Liberase TH (75 µg/ml, Roche, REF: 05401151001) and Liberase TM (75 µg/ml, 
Roche, REF: 05401127001) in Hank's Balanced Salt Solution (HBSS) buffer (Life 
Technologies, REF: 14175053). The cells were then collected to a 50 mL polypropylene 
falcon tube (Falcon©, Corning Inc., REF: 352070), excluding membranous tissues, and 
incubated with 15 mL of the liberase enzymatic solution for 30 min at 37οC. After, the cell 
suspension was homogenized and passed through a cell strainer (70 µm nylon filter from 
Corning Inc., REF: 352350) to obtain a single cell suspension. Cell viability was determined 
using Tripan blue solution (1:2) (Sigma, REF: T8154) and cells were ressuspended in 
Dulbecco´s Phosphate buffered saline (PBS) w/o Ca++/Mg++ (BioConcept, REF: 3-05F29-I) at 
a concentration of 2x107 live cells/mL. Finally 100 µL of this dispersed cell solution, 
containing 2x106 MMTV-PyMT tumor-derived cells, were injected in the third mammary fat 
pad of 9-10 week old syngeneic FVB female mice. 
 
3.2. mAbs and experimental design  
All the therapeutic mAbs used in this study were provided by Roche, including the 
bispecific mouse anti-ANG-2/VEGFA IgG1 (A2V) administered at 10-20 mg/kg; mouse IgG1 
(A2V control) at 20-40 mg/kg; rat anti-mouse CD40 agonistic IgG2a (FGK45) at 4 mg/kg; 
and rat IgG2a (FGK45 control) at 4 mg/kg. Each drug was injected in 200 µL of Dulbecco’s 
PBS w/o Ca++/Mg++ (BioConcept, REF:3-05F29-I), were the amount of Ab per injection was 
0,25-0,5 mg for A2V; 0,5-1 mg for mouse IgG1; 100 µg for FGK45; and 100 µg for rat IgG2a. 
Both the spontaneous and orthotopic MMTV-PyMT tumor models were employed, 
using the experimental design displayed in Figure 9. For the spontaneous MMTV-PyMT 
model (Figure 9 A), female MMTV-PyMT transgenic mice of 8-9 weeks old, correspondent 
to the adenoma stage in cancer development, were randomized in order to obtain 
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systematically similar groups with an identical age average. The treatments started 
immediately after the randomization, and included one control group with mice that 
received mouse IgG1 (20 mg/kg) (number of mice (n) = 8) and another group with mice 
treated with A2V (20 mg/kg) (n=6). Each mAb was administered by intraperitoneal (i.p.) 
injection, with a weekly schedule, and the mammary tumors were monitored biweekly. 
Transgenic MMTV-PyMT mice were euthanized when the tumor burden reached a critical 
size, according to protocols approved by the veterinary authorities.  
For orthotopic MMTV-PyMT tumors (Figure 9 B), following the transplantation of 
MMTV-PyMT derived-tumor cells (see previous section), the mice and tumor growth were 
monitored every other day, and the tumor size was measured using precision calipers. The 
tumor volume (mm3) was calculated as [(length/2) x (width/2) x height x π x 4/3]. Then, 
when the tumors reached an average of 200-300 mm3, the mice were randomized in order 
to have a similar tumor volume average (200-300 mm3), with identical number of mice, in 
each group, avoiding biased results. Immediately after the randomization the treatments 
started (day 0), delivering every mAb by i.p. injection, and the mice were sacrificed either 9 
days after the first injection (day 9 - Short-term treatment) or when the tumor burden 
reached the average of 1000 mm3 (day X - Long-term treatment). 
Figure 9. Schematics of the experimental design. Treatment schedules for (A) spontaneous 
MMTV-PyMT tumors and for (B) orthotopic MMTV-PyMT tumors. Blue arrow indicates the start of 
the treatments.   
The treatments of orthotopic tumors included one control group that received 
mouse IgG1 and rat IgG2a (CTRL IgGs), one group treated with A2V (+ rat IgG2a), one 
group treated with FGK45 (+ mouse IgG1), and a group that received the combination of 
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the two therapeutic Abs (A2V + FGK45). Only one dose of FGK45 and its isotype control 
(rat IgG2a) were administered, during the first injection, while the remaining Ab were 
administered weekly. For the short-term treatment, the number of mice (n), as well as the 
concentration of the mAbs, were as following: 
 - CTRL IgGs (n=5): 20 mg/kg of mouse IgG1; 4 mg/kg of rat IgG2a 
 - A2V + CTRL IgG (n=4): 20 mg/kg of A2V; 4 mg/kg of rat IgG2a 
 - FGK45 + CTRL IgG (n=4): 4 mg/kg of FGK45; 20 mg/kg of mouse IgG1 
 - A2V + FGK45 (n=4): 20 mg/kg of A2V; 4 mg/kg of FGK45 
 
For the long-treated tumors the settings were those described below: 
- CTRL IgGs (n=11): 40 mg/kg of mouse IgG1; 4 mg/kg of rat IgG2a 
 - A2V + CTRL IgG (n=10): 10 mg/kg of A2V; 4 mg/kg of rat IgG2a 
 - FGK45 + CTRL IgG (n=11): 4 mg/kg of FGK45; 40 mg/kg of mouse IgG1 
 - A2V + FGK45 (n=10): 10 mg/kg of A2V; 4 mg/kg of FGK45 
 
During necropsy, spontaneous and orthotopic tumors were harvested, using 
scissors and tweezers, and weighted using a precision balance. At this point the tumors 
were divided for posterior analysis, including histological analysis in stained tumor 
sections, flow cytometry analysis and gene expression analysis (not shown). In some cases, 
before euthanasia, the mice received intravenous (i.v.) injection of FITC-labeled lectin or 
i.p. injection of Pimonidazole (see perfusion and hypoxia studies).  
 
3.3. Histology 
For histology analysis the tumors were fixed for 4-6 hours in a 4% 
paraformaldehyde (PFA) solution, prepared by diluting a 32% PFA aqueous stock solution 
(Electron Microscopy Science, REF: 3291471) in Dulbecco’s PBS w/o Ca++/Mg++ 
(BioConcept, REF:3-05F29-I). Afterwards, the tumors were gradually transferred to sucrose 
(Sigma, REF: BCBN6225V) solutions (12-15-18-30%) in Dulbecco’s PBS w/o Ca++/Mg++ 
(BioConcept, REF:3-05F29-I). The samples were in each solution for approximately 24 
hours at 4οC, allowing to remove the water from the tumors. Finally the samples were 
embedded in O.C.T. compound (Cryomatrix™ from Thermo Scientific, REF: 6769006) and 
snap-frozen by cold fumes generated by dry-ice in a close container. The tumors were then 
preserved and stored in -80οC. For all histology analysis the tumors were sectioned using a 
Leica Cryostat (CM1850 or CM1950), with a thickness of 8 μm. Sections were placed in 
Superfrost Plus microscope slides (Thermo Scientific, REF: J1800AMNZ) and stored at 4οC, 
protected from light, before being stained.  
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3.4. Necrosis analysis 
To analyze the state of necrosis, Hematoxylin and Eosin staining (H&E) was 
performed in 8 μm frozen tumor sections (obtain as described above). To do so, the slides 
were hydrated with water and placed in Hematoxylin during 5 min for nuclear staining. 
This was followed by a wash and differentiation with 1% acid-alcohol for a few seconds. 
After washing in running water for 10 min, the slides were place in 0,25% Erythrosine 
(Eosin) solution during 1 min for cytoplasm staining. Finally, they were washed briefly in 
water, dehydrated and mounted using Eukitt (Sigma) mounting medium (Histology Core 
Facility, EPFL).  
Whole tumor sections were then acquired with the motorized Olympus slide 
scanner VS120-L100, with a 20x objective in brightfield mode. This scanner uses OlyVIA 
software to visualize the images, which has a file format (.vsi) incompatible with FIJI 
software (202). Therefore, acquired images were opened using the BIOP VSI Reader tool in 
Fiji, a plugin developed by the Bioimaging Core Facility of EPFL that allows to open .vsi files 
and convert them in other file formats (203).  
For this analysis necrotic tissue was assumed to be tissue where the Hematoxylin 
signal was absent, but where Eosin signal was present. Using the BIOP VSI reader the 
images were downscaled 16 times and converted in .tif format. In these pictures, 
displaying the entire tumor section, color deconvolution was applied, separating the 
Hematoxylin and Eosin channels, and the Huang threshold method was used to obtain 
binary masks for each channel. The eosin mask was cleaned using a closing operation (4 
iterations, count=2) and was assumed to represent total tissue area. To detect the necrotic 
area, a binary XOR operation was applied between the two masks. To estimate the density 
of necrotic tissue, the number of neighbors of each pixel that are part of the necrotic area 
were calculated, by averaging the binary image with a kernel of radius 9 pixels. A threshold 
was applied to this "Necrosis Density Map" to keep only areas with >50% necrosis. Finally, 
the regions were filtered by size (>5000 pixels) and the total area remaining was 
measured, which was considered as the necrotic area. Artifacts such as connective tissues, 
with a positive signal for necrosis, were excluded using ROI sets. Besides, tumor holes left 
by intensive necrosis, not detected by this method, were also delimited manually, their 
area was measured and added to the necrotic area. The percentage of necrosis for every 
tumor section was calculated as (Necrotic area/Total Tissue area)*100. 
 
3.5. Collagen analysis 
To evaluate the tumor collagen+ area a Sirius Red staining, specific for collagen 
fibers, was done on 8 μm frozen sections. First the sections were hydrated and stained 
with Weigert's working Hematoxylin solution for 10 min. Then the slides were washed in 
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tap water for 10 min, and placed in the Sirius red solution during 60 min for collagen 
staining. After, the slides were washed in two changes of acidified water and dehydrated in 
three changes of 100% ethanol. Lastly they were cleaned with xylene and mounted using 
Eukitt (Sigma) mounting medium (Histology Core Facility, EPFL). The results in light 
microscopy are the collagen fibers stained in red and the cytoplasm stained in yellow.  
Whole tumor sections were again acquired with the motorized Olympus slide 
scanner VS120-L100, with a 20x objective in brightfield mode. The images were then 
downscaled 8 times and converted in .tif format, using the BIOP VSI Reader. Afterwards, 
color deconvolution (FastRed FasBlue DAB) was used to separate the collagen fibers (red 
channel) from the cytoplasm (yellow-brown channel), on entire tumor sections. For both 
channels the ReniyEnropy threshold method was used to obtain binary masks, which were 
cleaned using the smooth operation (count =3), and the area limited to threshold was 
measured. The area measured in the red channel was assumed to be the Collagen+ area 
and the area measured in the yellow channel was assumed to be the Total tissue area. The 
percentage of the tumor Collagen+ area was calculated as (Collagen+ area/Total Tissue 
Area)*100.  
 
3.6. Perfusion Studies 
Perfusion studies were accomplished by in vivo labeling of perfused blood vessels 
with lectin from Lycopersicon esculentum (tomato). Lectin from tomato binds specifically 
to N-acetylglucosamine oligomers present on the luminal surface of the endothelium, 
therefore binding only to perfused and functional vessels (204). Before lectin injection, the 
mice were anaesthetized with 30 µL of Pentobarbital (150 mg/ml, from EPFL) 
intramuscular injection. When the mice were unresponsive, 100 µL of FITC-conjugated 
lectin from tomato (Sigma-Aldrich, REF: L0401-1MG, 2 mg/ml, diluted with Dulbecco’s PBS 
w/o Ca++/Mg++ (BioConcept, REF:3-05F29-I) to a final concentration of 1 mg/ml) was 
delivered into their bloodstream, by intraocular injection. After 10 min the mice were 
sacrificed by cervical dislocation, the tumors were excised and treated as describe in the 
Hystology section above. Direct visualization of FITC-conjugated lectin in tumor sections 
was possible, without secondary amplification, using a confocal microscope (see 
Immunofluorescence staining (IFS) and microscopy below).  
 
3.7. Tumor hypoxia studies  
In vivo labeling of tumor hypoxic regions was performed using Pimonidazole 
(PIMO), which at  pO2 ≤ 10 mmHg forms covalent bonds with thiol proteins in hypoxic cells, 
forming intracellular clusters detectable through immunohistochemistry (205). Mice were 
 30 
 
 Synergy between antiangiogenic and immuno- therapies in breast cancer 
injected i.p. with 200 µL of PIMO HCl (10 mg/ml, from Hypoxyprobe, Inc., REF: HP-100mg) 
and euthanized after 30 min by cervical dislocation. Tumors were then dissected and 
treated as described in the histology section above. To visualize hypoxic areas, 8 µm tumor 
sections were stained with a monoclonal antibody conjugated to Dylight™549 (HP-Red549 
from Hypoxyprobe, Inc., REF: HP7-x), that binds to PIMO clusters, and imaged using 
confocal microscopy (see IFS and microscopy below). 
 
3.8. Immunofluorescence Staining (IFS) and Microscopy  
For IFS, tumor sections (8 µm) were first hydrated and washed in PBS 1x solution 
for 10 min. This solution was prepared by dissolving PBS buffer 10x powder (Applichem, 
REF: 38210000) in ultrapure milli-Q water, obtaining a PBS 10x solution, which was then 
diluted to obtain 1x solution. Next, they were incubated with 0,3% Triton X-100 
(Applichem, REF: 34021300) solution, prepared in Dulbecco’s PBS w/o Ca++/Mg++ 
(BioConcept, REF: 3-05F29-I), for 30 min at room temperature (RT). This step was followed 
by 3 times 10 min wash with PBS 1x solution. Following, the tumor sections were blocked 
for 60 min at RT with Blocking solution, which contained 10% Fetal Bovine Serum (FBS) 
(EuroClone, REF: ECS0180D), 3% Bovine Serum Albumin (BSA) (Sigma, REF: A7906) and 
0,1% Triton X-100 (Applichem, REF: 34021300) in Dulbecco’s PBS w/o Ca++/Mg++ 
(BioConcept, REF: 3-05F29-I). After washing with PBS 1x solution 3 times for 10 min each, 
the sections were incubated with primary Abs diluted in blocking solution during 90 min in 
a dark and humid chamber at RT. Next, after 2 times 10 min wash with PBS 1x solution, the 
tumor sections were incubated with the secondary Abs diluted in blocking solution (if 
unconjugated primary Abs were used) for 60 min at 4οC. This step was followed by 2x10 
min wash with PBS 1x and 10 min incubation with DAPI (1 mg/ml solution was diluted in 
Dulbecco’s PBS w/o Ca++/Mg++ (BioConcept, REF: 3-05F29-I) to a final concentration of 1 
µg/ml, from Sigma, REF: D9542) for cell nuclei staining. Finally the sections were washed in 
PBS 1x solution for 5 min, mounted with DAKO™ fluorescence mounting medium (Agilent 
Technologies, REF: S3023) and covered with cover glass (Heathrow Scientific, REF: 10216). 
To avoid photobleaching the slides were preserved and stored at 4οC in the dark, before 
being imaged.  
In every IFS, tumor sections were incubated with a purified rat anti-mouse FcγII/III 
receptor (CD32/16) monoclonal antibody (5 µg /ml, Mouse Fc BlockTM, BD Biosciences, 
REF: 553142) diluted in the blocking solution, to avoid high background staining.  
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All Abs used in IFS, as well as their concentrations, are listed below: 
Marker Fluorochrome 
conjugated 
Host Reactivity Concentration 
used (µg/ml) 
Supplier 
CD31/PECAM-1 
(Clone: MEC 13.3) 
FITC Rat Mouse 10 BD Biosciences 
(553372) 
α-SMA 
(Clone: 1A4) 
Cy3™ Mouse Mouse, rabbit, 
goat, Human, … 
10-15 Sigma 
(C6198) 
NG-2 Unconjugated Rabbit Mouse, Human 
and monkey 
5 Millipore 
(AB5320) 
Rabbit IgG 
F(ab’)2 
Alexa Fluor® 647 Goat Rabbit 2-2,5 LifeTechnologies 
(A21246) 
CD8a 
(Clone: 53-6.7) 
Alexa Fluor® 647 Rat Mouse 4 BD Biosciences 
(557682) 
CD4 
(Clone: RM4-5) 
PE Rat Mouse 4 Biolegend 
(100512) 
PIMO Dylight™ 549 Mouse All species 10 Hypoxyprobe, Inc. 
(HP7-x) 
 
The majority of the Abs used were fluorochrome-conjugated, except for the 
primary rabbit anti-NG2 Ab, which was revealed by using the goat anti-rabbit Alexa Fluor-
647 conjugated secondary antibody.  
For imaging, the confocal microscope Zeiss LSM 700, with 
INVERT Zeiss AxioObserver Z1 stand was used. Both manual and motorized versions of this 
equipment were used, where the later was used to obtain tile scans. A 20x objective was 
used in all acquisitions, with a resulting 200x magnification of the tumor sections and a 
total sample image area of 409 600 µm2. The software used in this microscope, the ZEN 
2009, allowed sequential acquisition and pseudocoloration of fluorescent signals from 
individual fluorophores (single optical sections). 
 
 
3.9. Quantification of confocal microscopy images  
For all quantifications of images acquired with the confocal microscope, the FIJI 
open-source software was used. Multiple pictures (8-15) of each IF stained tumor section 
were randomly acquired and quantified. Following, the resulting values were averaged to 
obtain the mean values for each tumor/mouse. 
 
 32 
 
 Synergy between antiangiogenic and immuno- therapies in breast cancer 
a) Relative Vascular Area 
To quantify the relative tumor vascular area, IFS with anti-CD31 Ab conjugated with FITC in 
tumor sections or in vivo FITC-conjugated lectin labeling was perform (as previously 
described). Acquired images were quantified as followed: manual threshold (B&W) for 
positive signal was applied in CD31+ or lectin+ single fluorescence channels to obtain binary 
masks. Next the area (in µm2) limited to threshold was measured. The total imaged area 
was also measured to calculate the fraction area occupied by the CD31+ or lectin+ signal, 
which was defined by the CD31+ or lectin+ area divided by the total area. This values were 
then considered as the relative vascular area in each image.  
b) Hypoxic Areas 
Tumor hypoxic regions were quantified after in vivo injection of PIMO and ex vivo IFS with 
anti-PIMO Ab in tumor sections (previously described in 3.8). Manual threshold (B&W) for 
positive signal, in acquired pictures, was applied to the PIMO+ single fluorescence channel. 
The area (in µm2) limited to the threshold and the fraction area (PIMO+ area/total imaged 
area) was calculated by the software, where the later was considered as the relative 
hypoxic area in each image.  
c) Perivascular cell Coverage 
The proportion of tumor blood vessels covered by perivascular cells was assessed by IFS in 
tumor sections with a triple staining using Abs against CD31, NG2 and αSMA (as previously 
described in 3.8). For every marker-positive signal a binary mask was created by applying a 
manual threshold (B&W). Next the area (in µm2) limited to threshold as well as the faction 
area were measured in each image. Then, double positive NG2+CD31+ or αSMA+CD31+ and 
the triple positive NG2+αSMA+CD31+ fraction areas were calculated applying the binary 
AND operation (Image calculator) between the masks. This values, indicating marker-
positive vascular area fraction, were considered representative of the degree of 
association between NG2+, αSMA+ or both cells and blood vessels, respectively. Finally the 
fraction (%) of blood vessels covered by NG2+ and αSMA+ cells or both (NG2+αSMA+) was 
calculated by dividing double positive NG2+CD31+ or αSMA+CD31+ and the triple positive 
NG2+αSMA+CD31+ fraction areas by the CD31+ fraction area, respectively.  
d) Number of CD8+ and CD4+ cells  
Anti-CD8 and anti-CD4 Abs were used to visualize CD8+ and CD4+ cells in IF stained tumor 
sections (previously described in 3.8). Single CD8/4+ cells were counted in each picture, 
which corresponds to a microscopic field of 409 600 µm2. Due to high background signal in 
the CD8+ single fluorescence channel, the number of CD8+ cells per microscope filed was 
obtained by manual counting using the Cell Counter plugin in FIJI (206). CD4+ single 
fluorescence channel displayed low/inexistent background signal, allowing the use of the 
Analyze Particles FIJI tool to calculate the number of CD4+ cells per microscope field. To do 
so, a manual threshold (B&W) was applied to the CD4+ single fluorescence channel, since 
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automatic particle analysis requires a binary image. Then, overlapping cells were separated 
using the Watershed FIJI command. Finally, the Analyze Particles tool was used in these 
segmented binary images, with adjusted size and circularity to exclude non-specific objects 
(Size: 10-200 µm2; circularity: 0,2-1,0), obtaining the number of CD4+ cells.  
 
3.10. Flow cytometry analysis 
For flow cytometry analysis, half of each tumor harvested was processed to obtain 
a single cell suspension. For this purpose, following the excision during necropsy, the 
tumors were immediately placed in 15 mL falcon tubes (SPL Life Sciences, REF: 50015) at 
4οC and chopped with scissors. Then, they were incubated (in a shaker) with 2-4 mL of 
liberase enzymatic solution (75 µg/ml Liberase TH (Roche, REF: 05401151001) and 75 
µg/ml Liberase TM (Roche, REF: 05401127001) in HBSS buffer (Life Technologies, REF: 
14175053)) for 30 min at 37οC. Next, the resulting cell suspension was filtered by passing it 
through two 70 µm nylon filters (Corning Inc., REF: 352350) and washed in cold Dulbecco’s 
PBS w/o Ca++/Mg++ (BioConcept, REF: 3-05F29-I), obtaining a single cell suspension. 
Afterwards, the cells were centrifuged at 1500 rpm, 4οC for 5 min, the supernatant 
discarded and the cells ressuspended in ~100 µl of the Dulbecco’s PBS w/o Ca++/Mg++ 
(BioConcept, REF: 3-05F29-I). Following a second centrifugation (1500 rpm, 4οC, 5 min) the 
supernatant was discarded and the cells were incubated in the dark during 30 min at 4οC 
with a viability staining solution (LIVE/DEAD® Fixable Dead Cell Stain Kit, with blue 
fluorescent reactive dye, from Life Technologies REF:L23105). This solution was prepare by 
adding 50 µl of Dimethyl sulfoxide (DMSO) to the vial of the reactive dye (both provided by 
the kit), and was used with a 1:1000 dilution. The samples were subsequently centrifuged 
(1500 rpm, 4οC, 5 min) and washed with Dulbecco’s PBS w/o Ca++/Mg++ (BioConcept, REF: 
3-05F29-I). Following this step, the samples were incubated with a mix of Primary Abs, 
diluted in Dulbecco’s PBS w/o Ca++/Mg++ (BioConcept, REF: 3-05F29-I), for 15-30 min at 
4οC, protected from the light. The Ab mix included Abs against the surface markers CD45 
(0,7 µg/ml, APC-conjugated, from BD Biosciences, REF:559864), CD8a (0,5 µg/ml, Brilliant 
VioletTM 605-conjugated, from Biolegend, REF:100743) and CD4 (0,5 µg/ml, Brilliant 
VioletTM 785-conjugated, from Biolegend, REF:100551), as well as the rat anti-mouse 
FcγII/III receptor (CD32/16) antibody (5 µg/ml, Mouse Fc BlockTM, BD Biosciences, Cat: 
553142). Finally the samples were centrifuged (1500 rpm, 4οC, 5 min) and washed 2 times 
with Dulbecco’s PBS w/o Ca++/Mg++ (BioConcept, REF: 3-05F29-I) to eliminate the excess of 
Ab.  
Single cell suspensions were then analyzed using the BD Bioscience LSRII 
cytometer, a 5-laser and 18-detector analyzer. Antibody positive controls – a solution 
containing 0,5 µL of the Antibody linked to OneComp eBeads (eBioscience, REF: 01-1111) 
in 500 µL of Dulbecco’s PBS w/o Ca++/Mg++ (BioConcept, REF: 3-05F29-I) – and un-stained 
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(US) cell suspensions were used for compensation, with adjusted voltage to the beads or 
cell size. CD8+ and CD4+ cell subsets, gated on alive CD45+ cells were analyzed. Negative 
controls - cell suspensions stained with Fluorescence Minus One (FMO) solution 
(Dulbecco’s PBS w/o Ca++/Mg++ (BioConcept, REF: 3-05F29-I) with mouse Fc Block and all 
antibodies except one) - were required to determine the proper position of each gate.  
 
3.11. Statistical analysis  
 All statistical analysis and graphs presented were done using the GraphPad Prism 
6© software. In all cases values were expressed as mean ± Standard error (SEM). Statistical 
analysis were performed using two-tailed unpaired Student’s t test or ordinary one-way 
ANOVA with Tukey’s multiple comparisons test, as indicated in each figure, with 95% 
confidence intervals. Differences were considered statistically significant when p values 
were inferior to 0,05 (*, p < 0.05; **, 0.001<p< 0.01; ***, p < 0.001). 
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4. Results  
 
4.1. Simultaneous blockade of ANG-2 and VEGF-A inhibits tumor growth and increases the 
survival in mammary tumor models 
The therapeutic efficacy of double ANG-2/VEGF-A blockade was first evaluated in 
the MMTV-PyMT mouse model of breast cancer, one of the most aggressive pre-clinical 
models of mammary carcinoma, and poorly responsive to the current treatments. In 
parallel, the orthotopic MMTV-PyMT model, obtained by transplanting MMTV-PyMT 
tumor cells into the mammary gland of syngeneic wild type mice – FVB mice, was also 
employed.  
In order to study the anti-tumor effects of blocking ANG-2 and VEGF-A, a bispecific 
mouse mAb that neutralizes both ANG-2 and VEGF-A, termed A2V, was administered 
(116). As isotype control the MOPC21 antibody, a mouse IgG1 mAb with irrelevant 
specificity, was used and termed CTRL IgG.  
  Established orthotopic tumors (tumor volume of 200-300 mm3) were weekly 
treated with i.p. injections of either A2V or CTRL IgG. Mice were sacrificed either 9 days 
after the first injection (short-term treatment) (Figure 10 A), or when the tumor burden 
reached the average size of 1000 mm3 (long-term treatment) (Figure 10 B). Female 
spontaneous MMTV-PyMT transgenic mice of 8-9 weeks of age (in adenoma stage) were 
also treated weekly with i.p. injections of either A2V or CTRL IgG, and euthanized when the 
tumor burden reached a critical size (in late carcinoma stage), according to protocols 
approved by the veterinary authorities (‘survival’ study) (Figure 10 C). Tumor analysis was 
performed at the endpoint.   
A2V treatment led to a powerful inhibition of tumor growth in the orthotopic 
model (Figure 10 A and B). The mean tumor volume in orthotopic MMTV-PyMT mice, 
treated with A2V (Figure 10 A, left panel), showed a 70% tumor growth inhibition, when 
compared to mice treated with the CTRL IgG, during the short-term treatment. 
Respectively, the ex vivo tumor weight of A2V treated mice was reduce by ~50% (Figure 10 
A, right panel). Fifty percent of tumor growth inhibition was also observed during the long-
term treatment with A2V at day 42 (Figure 10 B), extending the survival by 2 weeks, 
comparing to control treated tumors.  
Furthermore, A2V treatment also increased the survival in spontaneous MMTV-
PyMT mice (Figure 10 C). According to the median survival, mice treated with A2V survived 
40 days longer, when compared to mice treated with control IgG (105 days vs. 145 days), 
with some mice living up to 154 days (all mice in the control group died by 115 days). 
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Collectively, the aforementioned data indicate that A2V treatment effectively 
impairs the progression of established orthotopic MMTV-PyMT tumors, both during the 
short- and long treatment schedule, and extends the survival also in the more clinically 
relevant and aggressive spontaneous MMTV-PyMT model. 
Figure 10. Dual ANG-2 and VEGF-A blockade inhibits tumor growth in both orthotopic and 
spontaneous MMTV-PyMT tumor models. (A) Volume and weight of orthotopic MMTV-PyMT 
tumors with short-term treatment; left panels illustrate the tumor growth (mean tumor volume ± 
SEM) following the treatment with A2V or the CTRL IgG, arrow indicates the start of the treatments; 
right panels show the ex vivo tumor weight expressed as fold change vs. CTRL IgG (mean values ± 
SEM), where each dot represents one tumor, derived from one mouse. (B) Tumor growth (mean 
tumor volume ± SEM) of orthotopic MMTV-PyMT tumors with long-term treatment; arrow indicates 
the start of the treatments. Statistical analysis by unpaired Student’s t test with 95% confidence 
interval. (C) Survival curve of spontaneous MMTV-PyMT mice, showing a median survival of 105 
days for mice treated with the CTRL IgG and 145 days for mice treated with A2V. Statistical analysis 
by Log Rank (Mantel-Cox) test (* = p value < 0.05; *** = p value < 0.001). 
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4.2. Dual blockade of ANG-2 and VEGF-A leads to increased necrosis in orthotopic MMTV-
PyMT mammary tumors, during early stages of tumor development 
 
The state of necrosis of MMTV-PyMT mammary tumors treated with A2V was 
assessed by performing Hematoxylin and Eosin staining (H&E) on tumor sections and 
measuring the percentage of the necrotic area (see materials and methods). Because 
spontaneous MMTV-PyMT mice at the endpoint have multiple aggressive tumors, with 
different stages of tumor progression – there is variability among the different individual 
tumors in each mouse – necrosis evaluation of these tumors may not reflect the real 
conditions. Conversely, progression of orthotopic tumors is synchronized, allowing to 
better evaluate the tumor response to therapy. Therefore, the state of necrosis was 
evaluated in orthotopic MMTV-PyMT tumors.  
Following this analysis, a significant increase of the necrotic area in orthotopic 
MMTV-PyMT tumors could be observed after a short-term treatment with A2V, comparing 
with the control (Figure 11 A, left panel). Of note, A2V treated tumors were more necrotic 
even though they were smaller than the CTRL IgG treated tumors (see Figure 10 A). 
However, this difference was not observed in long treated tumors (Figure 11 A, right 
panel), where both treatments lead to the same extent of tumor necrosis (~50% of tumor 
necrotic area). 
The ECM plays a key role in breast development and it is known to be involved in 
breast cancer progression: increased deposition of ECM, especially collagen fibers, leads to 
the formation of a fibrotic-like stroma that supports tumor progression and correlates with 
poor prognosis in breast cancer patients (207, 208). Therefore, the tumor collagen+ area 
was evaluated by performing a Sirius red staining (see materials and methods). For the 
same reasons mentioned above the orthotopic tumor model was used for this assessment.  
Although no significant differences were found between tumors treated with A2V 
and tumors treated with the CTRL IgG, a trend for increased Collagen+ area was found in 
orthotopic MMTV-PyMT tumor after A2V treatment in both treatment schedules (Figure 
11 B, left and right panels). 
Generally, A2V treatment increases necrosis of MMTV-PyMT tumors during the 
early stages of tumor progression, an effect that seems to be partially lost at the later 
stages of tumorigenesis. A trend of increased collagen deposition was also found after A2V 
treatment, likely due to inflammation/tissue repair processes due to increased 
necrosis/tumor cell death. 
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Figure 11. A2V leads to increased tumor necrosis during the early stages of orthotopic 
MMTV-PyMT tumor development, with a trend toward increased collage deposition. (A) 
Percentage of the necrotic area in orthotopic MMTV-PyMT tumors upon short-term treatment (left 
panel) and long-term treatment (right panel) with either A2V or CTRL IgG; top panels show 
quantitative analysis of the necrotic areas (mean values ± SEM), bottom panels show representative 
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pictures of the whole tumor sections, with necrotic areas highlighted in black (V=Viable area; 
N=Necrotic area). (B) Collagen positive area in orthotopic MMTV-PyMT tumors upon short-term 
treatment (left panel) and long-term treatment schedules (right panel); top panels represent 
quantitative analysis of collagen positive areas (mean values ± SEM), bottom panels show 
representative pictures of the whole tumor sections, with collagen fibers highlighted in pink-red. In 
all the graphs each dot represents one tumor, derived from one mouse. Statistical analysis by 
unpaired Student’s t test with 95% confidence interval (* = p value < 0.05). 
 
4.3. A2V treatment leads to tumor vasculature regression and angiogenesis inhibition in 
MMTV-PyMT mammary carcinomas 
 
 The antiangiogenic effect of ANG-2/VEGF-A blockade was then assessed in 
spontaneous and orthotopic MMTV-PyMT carcinomas. To do so, tumor blood vessels were 
analyzed on tumor sections stained with anti-CD31/PECAM Ab, to visualize the whole 
tumor vascular network, and/or after in vivo FITC-lectin perfusion to identify functional and 
perfused tumor blood vessels. Analysis of confocal microscope images revealed qualitative 
differences of the blood vessels between the 2 groups (Figure 12 A). While tumors treated 
with the CTRL IgG displayed a more dense and heterogeneous vascular network, A2V-
treated tumors showed intermittent and short blood vessels with a smaller diameter and 
poorly branched. Remarkably, dual ANG-2/VEGF-A blockade produced ample avascular 
areas, especially localized in the inner part of the tumor (Figure 12 B), suggesting that both 
inhibition of angiogenesis and vascular regression had occurred. In these tumors, blood 
vessels were mainly localized at the tumor periphery (Figure 12 B), suggesting that they 
may exploit the preexisting mature blood vessels of the host organ (that are less sensitive 
to antiangiogenic treatments) to receive supplies and support their progression, a 
mechanism termed vessel co-option. 
 Furthermore, the relative tumor vascular area was measured on these 
immunofluorescence stained tumor sections, where a drastic reduction of the tumor 
vascular area could be observed in both models and schedules after the dual ANG-2/VEGF-
A blockade (Figure 12 C, D and E). A consistent reduction in blood vessel density of ~50% 
could be found in every tumor analyzed, both in terms of lectin+ area (Figure 12 C) and 
CD31+ area (Figure 12 D and E).  
 Taken together, these data suggest that A2V is able to impair angiogenesis and leads 
to vascular regression, showing therefore a potent anti-angiogenic effect in these models 
of breast cancer.  
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Figure 12. Co-targeting ANG-2 and VEGF-A remarkably decreases tumor vasculature and 
inhibits angiogenesis in the MMTV-PyMT tumor models. (A) Representative pictures of the 
treated tumors, with CD31 (green) and DAPI (blue) immunofluorescence staining in spontaneous 
MMTV-PyMT tumor sections, analyzed immediately after discontinuation of therapy. The confocal 
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microscope magnification is 200x; scale bar, 100 µm. (B) Representative pictures with lectin (green) 
and DAPI (blue) showing avascular areas and the peripheral localization of tumor blood vessels 
(delimitated by the doted white line) in orthotopic tumors treated with A2V; tumors treated with 
CTRL IgG do not display this characteristic; the pictures are the result of tile scans (3x3) with a 
confocal microscope magnification of 200x; scale bar, 200 µm. Relative vascular area in orthotopic 
tumors, during short- (C) and long-term treatment (D), and in spontaneous tumors (E), is 
represented by the relative lectin+ area (C) or the relative CD31+ area (D and E). In every graph 
(mean values ± SEM) each dot corresponds to one tumor/mouse and displays the average of the 
analysis of 8-15 pictures per tumor. Statistical analysis by unpaired Student’s t test with 95% 
confidence interval (*** = p value < 0.001).  
 
4.4. Consistent with angiogenesis inhibition, ANG-2/ VEGF-A blockade leads to increased 
tumor hypoxia  
 
Antiangiogenic treatment and consequent vessel regression is known to increase 
tumor hypoxia (29), therefore tumor hypoxic areas were quantified using an anti-
pimonidazole (PIMO) staining (see Material and  Methods).  In this analysis, fewer and 
smaller hypoxic areas were detected in CTRL IgG treated tumors when compared to the 
A2V treated tumors (Figure 13 A), associated with their high or poor vascularization status, 
respectively. Quantitative analyses of the relative PIMO+ area (Figure 13 B) corroborated 
these observations, with a significant increase in tumor hypoxic areas following the 
treatment with A2V.  
Figure 13. ANG-2/VEGF-A blockade increases tumor hypoxia in orthotopic MMTV-PyMT 
tumors. (A) Representative pictures of lectin (green) and PIMO (red) immunofluorescence staining 
in orthotopic MMTV-PyMT tumor sections upon short-term treatment, analyzed immediately after 
discontinuation of therapy. The confocal microscope magnification is 200x; scale bar, 100 µm. (B) 
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Quantitative analysis of relative PIMO+ area (mean values ± SEM) in orthotopic tumors. Each dot 
corresponds to one tumor/mouse and displays the average of the analysis of 8-15 pictures per 
tumor. Statistical analysis by unpaired Student’s t test with 95% confidence interval (* = p value < 
0.05).  
 
4.5. ANG-2/VEGF-A blockade increases perivascular coverage of the remaining tumor blood 
vessels 
 
 It known that ANG-2 antagonism of ANG-1-mediated TIE-2 signaling causes 
detachment or loss of perivascular cells, such as pericytes, and consequent vessel 
destabilization (108). Therefore, the effect of A2V treatment on pericyte coverage of 
tumor blood vessels was also investigated is this study. For this purpose an 
immunofluorescence staining on spontaneous MMTV-PyMT tumor sections was 
performed, using an anti-NG2 (Neural-Glial 2) antibody, as a marker for pericytes; an anti-
αSMA (Smooth Muscle Actin) antibody, a marker expressed by smooth muscle cells, but 
also expressed in a subset of mature pericytes; and the anti-CD31 antibody to stain ECs.  
 The confocal microscopy pictures reveled decreased presence of both NG2+ and 
αSMA+ cells in the control tumors, when compared to the tumors treated with A2V (Figure 
14 A). Detail analyses of these pictures showed an increased NG2+ and αSMA+ cell 
coverage of blood vessels in tumors that received the A2V crossMab (Figure 14 B), while 
the majority of the blood vessels in the CTRL IgG treated tumors were poorly associated 
with these cells.  
 Quantitative analysis, showing the proportion of blood vessels covered by αSMA+ 
cells (Figure 14 C, left panel), NG2+ cells (Figure 14 C, middle panel) or double positive 
αSMA+NG2+ cells (Figure 14 C, right panel), confirmed the data above mentioned: the 
remaining tumor blood vessels after A2V treatment were significantly more coated with 
αSMA+ and NG2+ cells, when comparing to the tumor blood vessels of the control treated 
tumors.  
 Collectively, the aforementioned data indicate that A2V-mediated ANG-2/VEGF-A 
blockade increases mural cell coverage of tumor blood vessels, favoring vascular stability. 
In previous experiments (not reported), a similar phenomenon was observed using LC06 (a 
mAb that neutralizes only ANG-2, and not VEGF-A), suggesting that A2V increases 
perivascular coverage of tumor vasculature by enhancing the ANG-1/TIE-2 signaling, due to 
ANG-2 blockade, rather than the VEGF-A neutralization.  
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Figure 14. ANG-2/VEGF-A blockade increases the association between mural cells and ECs in 
the spontaneous MMTV-PyMT model. (A) Representative pictures of the CTRL IgG and A2V 
treated tumors, with CD31 (green), αSMA (red) and NG2 (magenta) immunofluorescence staining in 
spontaneous MMTV-PyMT tumor sections, analyzed immediately after discontinuation of therapy. 
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The confocal microscope magnification is 200x; scale bar, 100µm. (B) Enlargement of the insets in 
the pictures above, with additional nuclear staining (DAPI, blue) in the bottom panel. Scale bar, 
50µm. (C) Quantitative analysis of the proportion of tumor blood vessels covered by perivascular 
cells (mean values ± SEM); left panel: the proportion of blood vessels covered by αSMA+ cells is 
represented by the ratio between the CD31+αSMA+ area (degree of association between αSMA+ cells 
and blood vessels) and the overall CD31+ area; middle panel: proportion of blood vessels covered by 
NG2+ cells represented by the ratio between the CD31+NG2+ area and the overall CD31+ area; right 
panel: proportion of blood vessels covered by double positive αSMA+NG2+ cells represented by the 
ratio between the CD31+αSMA+NG2+ area and the overall CD31+ area. Each dot corresponds to one 
tumor/mouse and displays the average of the analysis of 8-10 pictures per tumor. Statistical 
analysis by unpaired Student’s t test with 95% confidence interval (* = p value < 0.05; *** = p value 
< 0.001). 
 
4.6. Combining A2V with agonistic anti-CD40 mAb further inhibits tumor growth in 
orthotopic MMTV-PyMT mammary mouse model, showing a synergistic anti-tumor effect 
 
 Because the tumor vasculature is known to directly suppress adaptive immune 
responses, the elimination of tumor blood vessels, through the use of antiangiogenic 
therapies, could, in theory, boost the efficacy of immunotherapeutic strategies (188). To 
test the veracity of this hypothesis, the A2V crossMab was combined with an anti-mouse 
CD40 agonistic mAb (clone FGK45, rat IgG2a).  
 The orthotopic MMTV-PyMT mouse model, obtained as previously described, was 
employed for this study, where the treatments started when the tumors were well 
established (about 300 mm3). Orthotopic tumor-bearing mice received injections of A2V, 
FGK45, the combination of the two (A2V + FGK45) or the appropriate control mouse IgG1 
(MOPC21) + rat. IgG2A, termed CTRL IgGs, according to either a short- or long-treatment 
schedule, already described above. In order to balance the total amount of mouse and rat 
immunoglobulins injected in each mouse, among the different groups, FGK45 and A2V 
were administered with mouse IgG1 (FGK45 + MOPC21) and rat IgG2A (A2V + rat IgG2A), 
respectively. This setting allows to consider and rule out possible unspecific antibody-
mediated effects, such as antibody-dependent cell-mediated cytotoxicity (ADCC) triggered 
by the binding of Fc receptors (FcR) to the Fc portion of our antibodies. Only one dose of 
the FGK45 mAb and its own control, rat IgG2A, was administered, in the beginning of the 
treatments, while the remaining Abs were injected (i.p.) weekly.  
 The mean growth of these orthotopic MMTV-PyMT tumors was then analyzed, 
where a similar effect in tumors treated with FGK45, as a monotherapy, and the control 
treated tumors could be perceived. This effect, observed both in short and long term 
treatment schedules (Figure 15 A and B, left panels), suggested that the FKG45-based 
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immunotherapy alone has no significant anti-tumor effect in this model. However, 
following the combination of FGK45 with A2V, a potent anti-tumor effect was observed.  
 In the short-term setting, no additive antitumor effect in combining A2V with 
FGK45 was detected. Indeed the volume of A2V + FGK45-treated tumors was reduced, 
compared to the control groups, at the same extent as the A2V monotherapy-treated 
tumors (Figure 15 A, left panel). In agreement with the mean tumor growth, ex vivo tumor 
weight was significantly reduced by 50% in tumors treated with A2V alone or the 
combination therapy, comparing to the FGK45 or control treated tumors (Figure 15 A, right 
panel).  
In tumors treated with a long-term schedule, a comparable tumor inhibition effect 
between the A2V monotherapy and the combination therapy was observed during the 
initial phase of tumor progression (Figure 15 B, left panel), reproducing the data obtained 
in the short-term schedule. However, in the late stage of tumor progression, a more 
pronounced tumor inhibition in the combination therapy treated mice could be observed, 
compared to the A2V treated mice. Importantly, A2V + FGK45 treatment remarkably 
prolonged the survival by 31 days when compared to the CTRL IgGs group, showing a 
strong therapeutic potential of combining CD40 agonists and tumor vascular disruption. As 
expected, no significant difference in ex vivo tumor weight was found (Figure 15 B, right 
panel), since the mice were sacrificed when the tumors reached the same volume (about 
1000 mm3). Next, the individual growth curves of tumors treated during a long term 
schedule were assessed (Figure 15 C). It could be observed that in both FGK45 and CTRL 
IgGs treated groups the tumor progression was aggressive, reaching the tumor volume 
average of 1000 mm3 in just 14 days after the beginning of the treatments (Figure 15 C, top 
panels). Tumors treated with A2V monotherapy reached the same volume average only 28 
days after the start of the treatment (Figure 15 C, left bottom panel), demonstrating that 
A2V alone was able to delay tumor progression (A2V doubled the survival of the mice, 
compared to FGK45 and CTRL IgGs). Moreover, A2V + FGK45 led to additional tumor 
progression delay, compared to the A2V monotherapy, since the tumor volume average of 
1000mm3 was only reached 51 days after the beginning of the treatment. More 
importantly, the combination therapy was capable to achieve three cases of stable disease 
(Figure 15 C, right bottom panel, grey rectangle), where the tumors kept nearly the same 
volume throughout the treatments. 
Taken together, these data suggest a strong anti-tumor effect mediated by the 
combination therapy with A2V and FGK45, suggesting a synergistic effect between A2V 
and the agonistic CD40 mAb FGK45. 
 46 
 
 Synergy between antiangiogenic and immuno- therapies in breast cancer 
Figure 15. Combining A2V with agonistic anti-CD40 mAb further inhibits tumor growth in the 
orthotopic MMTV-PyMT mouse model. Growth and weight of orthotopic MMTV-PyMT tumors 
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after short term treatment (A) or long term treatment (B): left panels illustrate the tumor growth 
(mean tumor volume ± SEM) where the arrow indicates start of the treatments; right panels show 
the ex vivo tumor weight expressed as fold change vs. CTRL IgGs (mean values ± SEM), where each 
dot represents one tumor, derived from one mouse. Statistical analysis by ordinary one-way ANOVA 
with Tukey’s multiple comparisons test (* = p < 0.05; ** = 0.001<p< 0.01); (C) individual tumor 
growth curves, following a long term treatment schedule with control IgGs (top left panel), FGK45 
monotherapy (top right panel), A2V monotherapy (bottom left panel) or the combination therapy 
(bottom right panel) with cases of stable disease highlighted inside the grey rectangle.  
 
4.7. The combination therapy with A2V and FGK45 increases necrosis of orthotopic MMTV-
PyMT tumors in the early stages of tumor progression, and enhances tumor fibrosis 
 
The state of tumor necrosis was subsequently evaluated as previously described, 
after the short-term treatment with FGK45 or the combination therapy. While FGK45 
alone did not augment tumor necrosis, compared to the control group (Figure 16 A left 
panel, and 16 B), in combination with A2V led to a remarkable increase of the tumor 
necrotic area, compared to the monotherapies and the control group (Figure 16 A left 
panel, and 16B). These tumors, almost completely necrotic (~90% of necrosis), were 
significantly more necrotic than the FGK45 or the control treated tumors, even though 
they were half of their size (see Figure 15 A). Furthermore, the combination therapy was 
able to further increase the tumor necrosis, when compared to the A2V monotherapy 
(~65% necrosis). These statistical differences could not be observed in the long-term 
treated tumors, where all treatments displayed a similar percentage of necrosis. However 
a trend for increased tumor necrosis still remained after the combination therapy (Figure 
16 A, right panel).  
Administration of agonistic CD40 mAb in pre-clinical studies was shown to shift the 
phenotype of TAMs from pro- to anti-fibrotic, facilitating the depletion of collagen, which 
leads to tumor regression (209). However, after analyzing the collagen+ area of these 
orthotopic MMTV-PyMT tumors (as previously described), an opposite effect could be 
observed. While the collagen+ area of FGK45-treated tumors was similar to those treated 
with the CTRL IgGs and the A2V monotherapy, tumors treated with both A2V and FGK45 
displayed a significant increase of the collagen+ area, suggesting an enhancement of 
fibrosis, during the short-term treatment (Figure 16 C, left panel, and 16 D). Furthermore, a 
trend for increased fibrosis following the combination therapy could also be observed 
during the long-term treatment (Figure 16 C, right panel). 
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Figure 16. Combining A2V with FGK45 further increases tumor necrosis in the orthotopic 
MMTV-PyMT model, and enhances fibrosis. (A) quantitative analysis of the necrotic percentage 
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area (mean values ± SEM) in orthotopic MMTV-PyMT tumors with short-term treatment (left panel) 
and long-term treatment schedules (right panel); (B) representative pictures of the whole tumor 
sections, with necrotic areas highlighted in black; (C) quantitative analysis of collagen+ percentage 
area (mean values ± SEM) in orthotopic MMTV-PyMT tumors with short-term treatment (left panel) 
and long-term treatment schedules (right panel); (D) representative pictures of the whole tumor 
sections, with collagen fibers highlighted in pink-red. In all the graphs each dot represents one 
tumor, derived from one mouse. Statistical analysis by ordinary one-way ANOVA with Tukey’s 
multiple comparisons test (* = p < 0.05; * = 0.001<p< 0.01). 
 
Taken together, these findings indicate that FGK45 with A2V-mediated 
antiangiogenic therapy leads to a potent anti-tumor effect that results in intensive tumor 
necrosis. This effect was stronger in the combination therapy than in either of the 
therapies alone, suggesting that these therapeutic mAbs act cooperatively to induce this 
response. It is possible that tumor cell death accomplished by A2V (by blocking oxygen and 
nutrient supply to tumor cells) enhances the effect of the FGK45 mAb: increased tumor 
antigens, released from dying tumor cells, can be presented by FGK45-activated APCs to 
cytotoxic T cells, leading to adaptive anti-tumor immune responses, further increasing 
tumor cell death. In this study, different from what has been reported in literature, the 
combination therapy induced an increase of fibrosis in orthotopic MMTV-PyMT tumors, an 
effect likely due to tissue repair processes, following the powerful necrotic-inducing effect 
of this treatment.   
 
4.8. FGK45 does not impair the anti-angiogenic effect of A2V in the orthotopic MMTV-PyMT 
mouse model 
 
It has been reported that the binding of CD40L to CD40 expressed on ECs activates 
the PI3K pathway, leading to the expression of angiogenic factors, such as VEGF-A, 
promoting angiogenesis (210-212). This led to the evaluation of angiogenesis, as previously 
decribed, in orthotopic MMTV-PyMT tumors treated with FGK45, either as a monotherapy 
or in combination with A2V. Following this analysis, a similar blood vessel morphology 
could be observed in tumors treated with FGK45 and those treated with the CTRL IgGs 
(Figure 17 A), which display a heterogeneous and dense vascular network. Quantitative 
analysis, with both relative lectin+ and CD31+ area (Figure 17 B and C, respectively), 
demonstrated comparable relative blood vessel area between the two groups, showing 
that FGK45 treatment did not influence tumor angiogenesis. 
 
Moreover, dual A2V + FGK45 therapy led to the same extent of angiogenesis 
inhibition as the A2V monotherapy (~50% ihnibition) in both short- and long-term 
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treatment (Figure 17 B and C). Besides, an intermittent and short morphology of the tumor 
blood vessels after the dual treatment was also detected, similarly to previously observed 
data in A2V treated tumors (Figure 17 A).  
 
In agreement with these results, an increase of the relative PIMO+ area (Figure 17 
D), and therefore tumor hypoxic areas (Figure 17 A), was also found after the treatment 
with A2V + FGK45, compared to the FGK45 monotherapy or the control treated tumors. 
Again this effect was similar to previously observations with A2V monotherapy.  
 
All together, these informations demonstrate that, opposite to data previously 
reported, FGK45 does not increase angiogenesis and does not impair the anti-angiogenic 
effect of the A2V crossMab.  
 
Figure 17. FGK45 does not impair the anti-angiogenic effect of A2V in orthotopic MMTV-
PyMT tumors (A) Representative pictures of tumor sections with lectin (green) and PIMO (red) 
immunofluorescence staining in the orthotopic MMTV-PyMT model, after a short-term treatment 
schedule. The confocal microscope magnification is 200x; scale bar, 100 µm. Quantitative analysis 
of the relative tumor vascular area (mean values ± SEM), showing the relative lectin+ area in short 
treated tumors (B) or the relative CD31+ area in long-treated tumors (C); (D) quantitative analysis of 
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relative PIMO+ area (mean values ± SEM) in short-term treated tumors. For every graph each dot 
corresponds to one tumor/mouse, and displays the average of the analysis of 8-15 pictures per 
tumor. Statistical analysis by ordinary one-way ANOVA with Tukey’s multiple comparisons test (* = 
p < 0.05; ** = 0.001<p< 0.01; *** = p < 0.001). 
 
4.9. FGK45 increases the tumor infiltration of CD8+ T lymphocytes, potentiating an adaptive 
anti-tumor immune response 
 In order to assess the adaptive immune response triggered by FGK45 treatment, the 
pool of T lymphocytes within the tumor microenvironment was evaluated. To do so, both 
immunofluorescence staining on tumor sections (Figure 18) and flow cytometry analysis of 
single tumor cell suspension (Figure 19) were performed.  
 To identify potential cytotoxic T lymphocytes, the CD8 surface marker was used in 
immunofluorescence staining of orthotopic MMTV-PyMT tumor sections, treated with a 
short-term schedule. CD4+ T lymphocytes were identified by their expression of CD4 
marker. Following, the number of CD8+ and CD4+ cells on these IF stained tumor sections 
were quantified, by counting individual cells present in each confocal microscope field 
(640x640µm) (see material and methods). This quantitative analysis exposed a statistic 
significant increase of the number of CD8+ cells per field in FGK45 treated tumors, alone or 
in combination, compared to the A2V monotherapy or control treated tumors (Figure 18 A 
and D). This suggests that FGK45 helps the recruitment and/or the activation/proliferation 
of effector T cells, supporting the mounting of an anti-tumor immune response. Moreover, 
even if not statistic, a trend for further increase of the CD8+ cell numbers after dual FGK45 
and A2V therapy was detected, when compared to FGK45 monotherapy. The amount of 
CD4+ cells within the tumor microenvironment was similar for all groups, with a slender 
increase in the combination therapy (Figure 18 B and E). The ratio between CD8+ and CD4+ 
cells was significantly raised after the treatment with FGK45, comparing to the A2V 
monotherapy and control treated tumors (Figure 18 C). Although no statistical differences 
were found, the CD8+/CD4+ cell ratio was also increased after the combination therapy.  
 However, not only the amount of tumor infiltrating T cells can influence an immune 
response, their localization within the tumor is also important. For instance, the presence 
of CD8+ effector T cells in the tumor core correlates with better prognosis in cancer 
patients, than their presence in the invasive margin of the tumor (213). In this study, while 
the presence of CD4+ cells was restricted to the blood vessel surrounding areas (Figure 18 
E) at the margin of the tumor, CD8+ cells could extravasate (Figure 18 F, left image) and 
spread more within the tumor tissue (Figure 18 D). Nonetheless, a limiting effect driven by 
hypoxia for the CD8+ cell proliferation was observed, since these cells were rarely seen 
overlapping with hypoxic areas (Figure 18 F, right image).   
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Figure 18. FGK45 increases the tumor infiltration of CD8+ T lymphocytes in orthotopic 
MMTV-PyMT tumors after the short-term schedule. Quantitative analysis of the number of 
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CD8+ T cells (A) or CD4+ T cells (B) per microscope filed, and the ratio of CD8+/CD4+ cells (C) (mean 
values ± SEM). For every graph each dot corresponds to one tumor/mouse, and displays the average 
of the analysis of 8-15 pictures per tumor. Statistical analysis by ordinary one-way ANOVA with 
Tukey’s multiple comparisons test (* = p < 0.05; ** = 0.001<p< 0.01). (D) Representative pictures 
with lectin (green) and CD8 (magenta) or (E) lectin (green) and CD4 (red) immunofluorescence 
staining in orthotopic MMTV-PyMT tumor sections. Microscope magnification is 200x; scale bar, 
100 µm. (F) left image illustrates CD8+ cells extravasation into the tumor, with lectin (green) and 
CD8 (magenta) immunofluorescence staining; right image illustrates the relative localization of 
CD8+ cells in concern to the blood vessels and hypoxic areas, with lectin (green), CD8 (magenta) and 
PIMO (red) immunofluorescence staining. Microscope magnification is 200x; scale bar, 50 µm. 
 
 For the long-term treated tumors, the tumor infiltrating T cells were analyzed using 
flow cytometry analysis. To do so, whole tumors were processed in order to obtain single 
tumor cell suspensions (see materials and methods for detailed description). Single cells 
were then incubated with a viability staining, allowing to differentiate alive from dead cells, 
since only cells with disrupted membrane, therefore dead cells, are stained. Finally the 
tumor cell suspension was stained with 3 surface markers, CD45, CD8 and CD4 for the flow 
cytometry analysis. The gating strategy used is represented in Figure 19 A: after excluding 
debris (1st gate – SSC x FSC) and doublets (2nd gate - FSC-H x FSC-A and 3rd gate - SSC-H x 
SSC-A), cells were gated with the viability staining and the CD45 marker (4th gate), where 
alive CD45+ cells were identified with low viability staining (indicating membrane integrity 
and therefore alive cells) and high CD45 surface staining. CD8+ and CD4+ cells were then 
gated on alive CD45+ cells. The right controls (Fluorescence Minus One – FMO) were used 
to identify the proper placement of the gates.  
 During this analysis a slight increase of the CD8+ cell percentage, among the alive 
CD45+ cells, was observed in tumors treated with FGK45 (Figure 19 B). While this 
difference was not statistically significant compared to the control treated tumors, a 
statistic difference between the FGK45 and the A2V monotherapy treated groups could be 
observed, where the later displayed a small decrease in the CD8+ cell compartment. 
However, tumors treated with both A2V and FGK45 increased significantly the CD8+ cells, 
compared with the control and the A2V monotherapy. Although not statistically different 
from the FGK45 monotherapy, the combination therapy displayed once more a trend for 
further increase in the percentage of CD8+ cells. Even though no differences were found in 
the percentage of CD4+ cells among the different treatments (Figure 19 C), the ratio 
between CD8+ and CD4+ cells was found increased in tumors treated with FGK45, either 
alone or in combination with A2V (Figure 19 D).  
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Then, each individual tumor growth curves were compared with its corresponding 
CD8+ cell percentages in the combination therapy group. Following this analysis, a 
correlation between cases of stable disease (see Figure 15 C, bottom right panel, grey 
rectangle) - displayed as black dots in Figure 19 - and high percentages of CD8+ cells (Figure 
19 B) as well as high CD8+/CD4+ cell ratios (Figure 19 D) was detected. Although the 
number of these stable tumors is still low to draw conclusions, these data suggests that 
the high influx of CD8+ cells into the tumor correlates with a better anti-tumor response in 
the combinatory therapeutic approach.  
 
 
Figure 19. Combining A2V with FGK45 remarkably increases the percentage of CD8+ cells in 
orthotopic MMTV-PyMT tumors treated after the long-term schedule. (A) flow cytometry 
scatter plots demonstrating the gate strategy adopted (FSC – Forward Scatter; SSC – Side Scatter; A 
– Area; H – Height). Quantitative analysis of the percentage of CD8+ cells (B) or CD4+ cells (C), gated 
on alive CD45+ cells, and the ratio of CD8+/CD4+ cells (D) (mean values ± SEM), in single cell 
suspensions of orthotopic MMTV-PyMT tumors treated for a long term schedule. For every graph 
each dot corresponds to one tumor/mouse and black dots in the combination therapy group 
indicate the cases of stable disease. Statistical analysis by ordinary one-way ANOVA with Tukey’s 
multiple comparisons test (*, p < 0.05; **, 0.001<p< 0.01; ***, p < 0.001). 
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 In conclusion, FGK45 treatment potentiates an anti-tumor immune response in the 
orthotopic MMTV-PyMT model, by increasing tumor infiltration of CD8+ T lymphocytes. 
These changes in the normal lymphocyte compartment appear more profound after the 
combination of FGK45 with A2V, a synergistic effect likely due to the elimination of the 
immune suppressive tumor ECs, achieved with A2V treatment, which potentiates the 
immune effect of FGK45. Furthermore, the fact that FGK45 could increase the percentage 
of CD8+ cells at the endpoint, in tumors treated for a long schedule, suggests that the only 
dose of FGK45 administered is effective even in later stages of tumor progression.     
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5. Discussion and Conclusions 
Despite the promising activity of antiangiogenic drugs in pre-clinical tumor models, 
breast cancer patients treated with anti-angiogenic therapies show no apparent benefit 
from the therapy since, so far, all clinical studies of antiangiogenic therapies in breast 
cancer failed to improve OS (121). The majority of the current anti-angiogenic therapies in 
breast cancer are based on VEGF function inhibition. However, unlike other human 
cancers, there is no reported constitutive activation of the VEGF pathway in breast cancer 
(214). Therefore, breast cancer patients may benefit from therapeutic strategies targeting 
other angiogenic factors, such as the ANGs. Indeed high levels of ANG-2 correlate with 
poor prognosis in breast cancer patients (100). Nonetheless, the ANG-1 and ANG-2 target 
agent, AMG 386, displayed no clinical benefit in metastatic breast cancer patients in a 
phase II trial (126). 
Nevertheless, high levels of both VEGF-A and ANG-2 correlate with worse prognosis 
in breast cancer patients, when compared with cancers expressing high levels of either 
alone (114). This information, as well as previous pre-clinical studies demonstrating the 
synergistic angiogenic inhibition effect achieved with dual ANG-2 and VEGF-A (95-97), led 
to the evaluation of the therapeutic efficacy of double ANG-2/VEGF-A blockade, using the 
A2V crossMab, in the aggressive MMTV-PyMT mouse model of breast cancer. 
The findings of this study demonstrate that simultaneous blockade of ANG-2 and 
VEGF-A leads to powerful inhibition of tumor progression (50 to 70% inhibition) and 
increases the survival in this mouse model of breast carcinoma, as previously shown in 
other models (116, 215). Given that transgenic MMTV-PyMT mice die around 16 weeks of 
age due to the development of multiple aggressive carcinomas, the fact that some MMTV-
PyMT mice treated with A2V were able to live up to 22 weeks of age is a remarkable 
achievement. Furthermore, A2V also led to increased necrosis in orthotopic MMTV-PyMT 
tumors, in agreement with studies reported by Hashizume et al., where increased 
apoptosis of tumor cells was observed after dual ANG-2 and VEGF-A blockade (96).  
A2V tumor growth inhibitory effects were associated with the reduction of the 
overall tumor blood vessel density. Quantitative analysis of the relative tumor vascular 
area (CD31+ % area) demonstrated a drastic reduction of blood vessels in tumors treated 
with A2V, where the remaining blood vessels display a short, small diameter and poorly 
branched morphology. Perfusion studies demonstrated that A2V is also capable of 
decreasing blood vessel functionality. Furthermore, after ANG-2/VEGF-A blockade, blood 
vessels were mainly located at the tumor periphery, leaving large avascular areas in the 
central core of the tumor, which suggests the occurrence of vascular regression.  
Tumor revascularization upon VEGF target therapies have long been reported (29, 
94), where the upregulation of ANG-2 has been one of the nominated mechanisms of 
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resistance to this therapies (95).  In the present study, in agreement with those performed 
by Kienast et al. (116), a consistent fifty percent reduction of the blood vessel density was 
found in every tumor after A2V treatment, even in those treated for an extended period of 
time, with no reports of revascularization. Therefore, dual ANG-2/VEGF-A blockade impairs 
not only sprouting angiogenesis but also revascularization, displaying a potent anti-
angiogenic effect in the MMTV-PyMT mouse model of breast cancer.     
Although not demonstrated in this study, it can be speculated that this strong anti-
angiogenic effect may be partially mediated by the ANG-2 blockade effect on TEMs: 
blocking ANG-2 can impede TIE-2 upregulation by TAM/myeloid cells and their association 
with tumor blood vessels (98, 108). Given that TAMs are known to potentiate tumor 
angiogenesis in breast cancer (83), impairing the pro-angiogenic functions of TEMs could 
contribute to the anti-angiogenic effect of A2V.   
Consistent to angiogenesis inhibition and vessel regression, A2V also led to 
increased tumor hypoxia. It has been reported that increased tumor hypoxia drives 
therapeutic resistance and it’s a strong stimuli for tumor angiogenesis (216, 217), however 
the findings of this study indicate otherwise. The tumor ability to escape hypoxia by 
vascular remodeling was drastically impaired in tumors treated with A2V, where tumor 
cells had no access to oxygen or nutrients, explaining the intense tumor cell death/necrosis 
in hypoxic areas. 
Another finding of this study was the increased perivascular coverage of the 
remaining tumor blood vessels after A2V therapy. While the control treated tumors 
displayed blood vessels unevenly covered by perivascular cells, suggesting active 
angiogenesis, dual blockade of ANG-2/VEGF-A mediated by A2V increased mural cell 
coverage of the remaining tumor blood vessels, favoring vascular stability/normalization. 
Although not demonstrated here, it is possible that this effect is derived from the ANG-2 
blockade, rather than VEGF-A blockade. Several studies support this theory (95, 98), 
including unreported experiments of this study using the ANG-2 neutralizing mAb, LCO6, 
where a similar effect could be observed. Therefore, A2V-mediated ANG-2 blockade may 
increase the ANG-1/TIE-2 signaling, due to increased ANG-1 bioavailability, promoting 
accumulation of adhesion molecules in cell–cell junctions and increasing pericyte coverage 
(107). 
Given the blood vessel normalization effect mediated by A2V, as well as numerous 
studies recognizing the anti-metastatic effect of ANG-2 blockade (98, 116, 218, 219), it is 
reasonable to consider that A2V could also decrease tumor invasiveness and the frequency 
of metastatic dissemination. Besides, decreased blood vessel leakage accomplished by the 
maturation and stabilization of the remaining tumor blood vessels may increase the 
penetration of other drugs, such as chemotherapy (220). More importantly, the vascular 
normalization can create an immunosupportive microenvironment, which may improve 
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cancer immunotherapy (221). As stated previously, tumor blood vessels are typical 
abnormal, resulting in impaired blood vessel perfusion (222). This results in a hypoxic and 
acidic suppressive microenvironment that helps cancer cell evade the immune system, 
either by impairing the recruitment of cytotoxic lymphocytes, by upregulation of immune 
checkpoint molecules, such as PD-L1, by preferential recruitment of pro-tumoral Tregs or 
by impairing the function of resident immune effector cells (through the upregulation of 
TGF-β and IL-10) (223). While high doses of anti-angiogenic therapies lead to excessive 
vessel pruning and aggravation of this effect, low doses (or therapies targeting blood 
vessel normalization pathways, such as blockade of ANG-2) can lead to blood vessel 
normalization. This in turn can lead to lower increase in tumor hypoxia, enhancing the 
delivery of immune effector cells into tumors and creating a more immunosupportive 
microenvironment (221). Indeed, studies performed by Huang et al., revealed that low 
doses of the DC101 anti-VEGFR2 Ab, but not high doses of the same Ab, lead to tumor 
vascular normalization in a breast cancer model (224). The authors observed that the 
vascular normalization was responsible for increased tumor infiltration of CD8+ T cells and 
for the polarization of TAMs to an anti-tumor M1-like phenotype. This suggests that 
combining A2V with other therapies is a promising approach that should be further 
investigated. 
In summary, targeting both ANG-2 and VEGF-A, through the action of A2V, induces 
durable tumor growth inhibition and vascular regression with normalization of the 
remaining tumor blood vessels. The strong anti-tumor effect of this molecule, 
characterized by Kienast et al. (116), supported its investigation in clinical trials, in patients 
with advanced or metastatic solid tumors (NCT01688206).  
Taken the information above described, as well as the immunosuppressive role of 
ECs and tumor-derived VEGF-A in the tumor microenvironment (188), it was asked if a 
CD40 agonist (FGK45)-mediated immunotherapy could benefit from the combination 
therapy with A2V, in the mammary carcinoma mouse model, MMTV-PyMT.  
It was observed that, while FGK45-based immunotherapy alone was not able to 
inhibit the growth of orthotopic MMTV-PyMT tumors, the combination therapy (A2V + 
FGK45) leads to a remarkable tumor growth inhibition, suggesting a potential benefit in 
this combined therapeutic approach. Moreover, the tumor growth inhibition effect of the 
combination therapy was even more pronounced than the one observed after the 
treatment with A2V alone, during later stages of tumor progression. In addition, combining 
A2V with FGK45 led to the establishment of cases of stable disease (3 out of 10 mice 
treated with the combination therapy), which is suggestive of a synergistic anti-tumor 
effect between these two mAbs.  
In agreement with the aforementioned effect, a further increase in necrosis of 
orthotopic MMTV-PyMT tumors was also observed after the combination therapy, 
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compared to the monotherapies. This resulting intensive necrosis is an effect most likely 
mediated by the dual action of A2V and FGK45: it is reasonable to consider that tumor cell 
death mediated by A2V leads to increased presentation of tumor antigens to cytotoxic T 
cells by FGK45-activated APCs, enhancing adaptive anti-tumor immune responses. 
Furthermore, since breast cancer cells can also express CD40 (168), it is possible the 
occurrence of a direct apoptotic action of FGK45 on CD40 expressing MMTV-PyMT tumor 
cells, as previously reported (170). A possible T-cell independent anti-tumor activity of 
CD40-activated macrophages (166, 225) cannot also be excluded. 
Since agonist CD40 mAbs were shown to decrease fibrosis (209), the percentage of 
the collagen positive tumor area was also assessed. However, differently from the 
reported data, a significant increase of the collagen+ area in tumors treated with both A2V 
and FGK45 was found in this study. This contradictory effect may be due to tissue repair 
processes, mediated by the powerful increase in tumor necrosis.   
Moreover, despite several studies indicating the pro-angiogenic effect of CD40 
signaling in ECs (210-212), in this study comparable relative blood vessel areas were found 
between tumors treated with FGK45 and the control treatment. Besides, dual A2V + FGK45 
therapy led to the same extent of angiogenesis inhibition as the A2V monotherapy, 
suggesting that FGK45 does not increase angiogenesis and does not impair the anti-
angiogenic effect of the A2V. 
Following, it was evaluated whether the potent anti-tumor effect mediated by this 
combination approach was associated with an increase in adaptive anti-tumors immune 
responses, mainly by evaluating the tumor infiltration of T lymphocytes. Using two 
different techniques, IFS and flow cytometry, an increased infiltration of CD8+ cells in 
FGK45 treated tumors was detected, compared to the A2V monotherapy or control 
treated tumors. These results are in agreement with previous studies, where the 
administration of CD40 agonistic Abs was able to increase the number of tumor infiltrating 
CD8+ T cells (226, 227). This increase can be explained by the enhanced differentiation and 
function of APCs through FGK45 engagement, which leads to recruitment and/or the 
activation/proliferation of effector T cells, supporting the mounting of an anti-tumor 
immune response. Studies performed by Fransen et al., using the same CD40-agonistic 
mAb clone (FGK45), have disclosed that FGK45 activates local tumor-specific CD8 T cells, 
by inducing local but not systemic DC activation (228). However, in this study extravasation 
of CD8+ cells into the tumors could be observed, suggesting that the FGK45-activated APCs 
may travel from the tumor site to secondary lymphatic organs, where they actively present 
the tumor antigens to Naïve CD8+ T cells, leading to their activation and recruitment to the 
tumor. Therefore the increase of tumor infiltrating CD8+ cells observed after the treatment 
with FGK45, may be due to both recruitment and/or activation of local effector T cells. 
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A trend for further increase of the CD8+ cell numbers after dual FGK45 and A2V 
therapy was also observed, when compared to FGK45 monotherapy. This would be easily 
explained by the eliminating the tumor immunosuppressive ECs due to A2V therapy, and 
thereby the reduction of the negative regulation of adaptive immune responses. However, 
there was no statistic difference in the CD8+ cell numbers between the FGK45 and the 
combination treated tumors. One possible reason explaining the stronger anti-tumor 
effect achieved by the combination therapy, would be that the tumor infiltrating CD8+ cells 
present in this case are more activated or more antigen-specific compared to those in 
tumors treated with FGK45 alone. Further experiments using Ovalbumin-positive cancer 
models, such as the B16-OVA expressing melanoma cancer, would be the next logical step 
to assess a possible enhanced generation of antigen-specific CD8+ T cells after the 
combination therapy, by checking their expression of OVA-Specific TCR using flow 
cytometry with double CD8 and OVA-Specific TCR cell surface staining. Evaluation of the 
CD8+ cell activated status - by assessing their expression of perforin (both protein and 
mRNA levels, by ELISA or qPCR assays, respectively), IFN-γ and/or IL-2 (with intracellular 
cytokine staining in flow cytometry) -, or proliferation status – using the  
Bromodeoxyuridine (BrdU) Cell Proliferation Assay, a synthetic analog of the thymidine, 
which is incorporated into replicating DNA in dividing cells and can be subsequently 
detected by anti-BrdU antibodies -, are also necessary future studies.  
The numbers of tumor infiltrating CD4+ cells were similar between all the therapies, 
however the ratio between CD8+ and CD4+ cells, which correlates with good prognosis 
when increased (229), was significantly raised after the treatment with FGK45, either alone 
or in combination with A2V. Moreover, CD8+ cells were more spread into the tumor tissue, 
rather than limited to the blood vessel surrounding areas at the invasive margin of the 
tumor, which is also a good prognostic factor in cancer patients (213). 
Surprisingly, a slight decrease in the tumor infiltrating CD8+ cells after A2V 
treatment could be observed. This effect was reproducible, as it was continuously 
observed in non-reported experiments of this study. Since CD8+ cells rarely overlap with 
hypoxic areas, it is tempting to speculate that the decrease in the numbers of CD8+ cells 
may be due to the increase of hypoxic areas in tumors treated with A2V. While in the A2V 
monotherapy increased hypoxia seems to be a limiting effect for CD8+ cell proliferation, in 
the combination therapy this effect is most likely overpowered by the FGK45 effect.   
An association between the cases of stable disease, achieved by the combination 
therapy, and increased tumor infiltration of CD8+ cells was also detected in this study. 
Given that increased numbers of infiltrating CD8+ T cells have been associated with better 
clinical outcomes in patients with breast cancer (179), the high influx of CD8+ cells into 
these tumors was possibly responsible for the remarkable anti-tumor responses observed. 
These findings have important implications for the use of anti-CD40 therapies in breast 
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cancer patients. Given that therapeutic strategies relying solely on agonistic CD40 mAbs 
lead to clinical safety but not OS in patients with advanced solid tumors (176), the 
combination therapy with anti-angiogenic therapies would be a promising approach. 
Taken together, combining A2V with FGK45 leads to a strong anti-tumor response 
in the orthotopic MMTV-PyMT tumor model, with addictive inhibitory effects compared to 
each therapy alone. An hypothetical mechanism for the synergist effect between A2V- and 
FGK45-based therapies is proposed in Figure 20, explained by the creation of an 
immunosupportive microenvironment followed by A2V therapy, given that this therapeutic 
approach leads to (a) vascular regression and elimination of the immunosuppressive tumor 
ECs and tumor derived VEGF-A, decreasing the negative immune regulation with 
consequent increase immune activation triggered by FGK45, and to (b) the normalization 
of the remaining tumor blood vessels, which is permissive to T cell tumor infiltration. 
Besides, A2V also leads to (c) augmented tumor cell death, increasing tumor antigen 
uptake by tumor resident APCs (DCs and Macrophages), which upon FGK45 therapy 
become activated and increase tumor antigen presentation to Naïve CD8+ T cells (in either 
secondary lymphatic organs or in the tumor) resulting in their activation and/or 
recruitment, with consequent increased immune-mediated cell death. However, further 
studies aiming to evaluate the activated/proliferating status of CD8+ cells, as well as their 
specificity, are required to further understand the mechanisms behind this cooperative 
effect. 
Figure 20. Synergistic effect between A2V-based antiangiogenic therapy and FGK45-
mediated immunotherapy (Adapted from Kamrava, et al., Mol. BioSyst., 2009 (230)) 
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In conclusion, there is a clear benefit in combining A2V-mediated anti-angiogenic 
therapy with FGK45-mediated immunotherapy in the aggressive MMTV-PyMT pre-clinical 
model of breast cancer. However, MMTV-PyMT tumors resemble the Luminal B molecular 
subtype of human breast cancer, which accounts for 10-20% of all breast cancer cases (9). 
Therefore, it would be of interest to assess the anti-tumor effect of this therapy in other 
breast cancer mouse models, such as models of the Luminal A molecular breast cancer 
subtype, since they correspond to 50 to 60% of all cases, or models of the basal-like 
subtype, such as MMTV-Wnt1 transgenic mouse model (231), since they display the worst 
prognosis in human breast cancer patients (232). Besides, this combinatory approach 
might be improved if the cancer cells themselves are simultaneously targeted, using direct 
anti-cancer therapies such as chemotherapy or radiation therapy. Given that targeting 
different aspects of the tumor biology may produce better clinical benefit for cancer 
patients, especially with late-stage disease (230), this should also be assessed in a near 
future. 
Taken everything into consideration, it is my opinion that the combinatory A2V- 
and FGK45-mediated therapy should be further addressed and potentially translated to 
the breast cancer clinical settings. 
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